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Abstract 
Chemical protein synthesis is an invaluable tool that enables the construction of novel protein 
design, incorporation of non-native functionalities, elucidation of structure-function relationships 
and enable a wide diversity of modifications (such as Post Translation Modification) to study 
protein functions. Native Chemical Ligation (NCL) in conjunction with Fmoc Solid Phase Peptide 
Synthesis (SPPS) is the most used method for synthesis of functional peptides and proteins. The 
synthesis relies on the reaction of a C-terminal peptide thioester and a N-terminal cysteine peptide. 
Fmoc SPPS of peptide thioester for chemical protein synthesis via NCL is a challenge. Methods 
that exist for the synthesis of peptide thioester by Fmoc SPPS require special resins, linkers, 
additional chemistry and is difficult and time consuming.  Therefore, a simple and robust method 
to synthesize peptide thioester is highly desirable.  
Chapter two of this thesis describes the development of a versatile approach for direct synthesis 
of peptide thioesters from a solid support utilizing Fmoc chemistry. The method utilizes a cyclic 
urethane activation technique for the synthesis of peptide thioesters directly from solid support. 
The resulting thioester is stable and free of epimerization. The usefulness of this methodology was 
demonstrated by the synthesis of a 19 amino acid peptide thioester, which was utilized for the 
synthesis of a 29 amino acid long peptide derived from rabies virus glycoprotein (Rvg) using NCL. 
This accessible and robust Fmoc-based thioesterication technique provides a significant advance 
to chemical protein synthesis due to its uncomplicated nature, whereby eliminating special 
precautions and additional steps typically needed for synthesis of peptide thioesters. This approach 
can be used to incorporate post-translational modifications for the synthesis of complex post 
translational peptides and proteins in milligram quantities that can be used to study their structure 
and function. This modification approach can also be used for the synthesis of other complex 
protein modifications through residue specific N-terminal chemical modification by NCL. 
iv 
 
Chemical modification of protein is a critically important tool for various biological applications 
such as probing protein dynamics, elucidating protein structure and functions, enhancing protein 
stability in biological system and construction of protein-drug conjugates. Traditional 
modification techniques utilize non-specific lysine and cysteine conjugation strategies that 
produces a heterogenous mixture of conjugates. Over the last two decades there has been an 
increasing need to developed methods which would modify protein in a controlled manner.  
Chapter three describes the development of a novel site-specific Secondary Amine Selective 
Petasis (SASP) bioconjugation strategy using Petasis reaction to modify secondary amines and N-
terminal proline. The SASP reaction has been shown to modify a wide variety of peptides and 
proteins with high selectivity for N-terminal proline. The resulting bioconjugate is highly 
stereoselective (de >99%) which can be useful in drug discovery. Also, the multicomponent nature 
of this conjugation technique enables dual labeling of complex proteins in one pot with various 
cargoes such as dye, biotin and alkynes. The applicability of the SASP bioconjugation technique 
was demonstrated on a variety of different peptides and proteins with various aldehyde and 
organoboronate derivatives. The chemo-, regio- and site-specific nature of this method will enable 
the construction of biomolecular hybrids that can be used to study protein functions, identify new 
drug targets, deliver potent therapeutics to cellular targets, and engineer new materials. This 
strategy also provides a powerful tool to study the function and dynamics of post-translational 
modification such as mono methylated lysine that regulates transcription factor function. 
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Chapter 1 
General Introduction to Protein Chemistry, Chemical Synthesis 
and Site-Specific Modification Strategies  
1.1 General Introduction to Peptide and Protein Structure 
Protein are among the most abundant organic molecules in living system.1 The many unique three-
dimensional structures of protein make these  structure and function more diverse than any other 
class of macromolecules. Peptides and proteins serve a variety of functions within and outside the 
cell. They act as structural support for cells and tissues, enzymes, hormones neurotransmitters, 
growth factors, ion channel ligands, and toxins. The inherent high affinity and specificity of 
peptides and proteins for their respective targets led them for significant roles as medicines.2 
Diseases such as cancer, diabetes, cardiovascular disease, asthma and autoimmune diseases are 
treated with peptide or protein-based drugs.3 Proteins are polymers formed from a sequence of 
amino acids. Peptides are small polymers of amino acids (fewer than 50 monomer units) that is 
distinguished from protein by their size.4 Amino acids are the building blocks of the polypeptides 
of peptides and proteins. They are small organic molecule that consists of a carboxyl group 
(COOH), an amine group (NH2), an alpha carbon and a variable side chain-R group (Figure 1.1). 
 
Figure 1.1  General structure of amino acid. Image created with ChemDraw. 
2 
 
The variable R group have different chemistries that determine the specific characteristic of the 
amino acid, including size, pH and polarity. Amino acids are classified as acidic, basic, polar or 
non-polar depending on the variable R group. Peptides and proteins are built from 20 natural amino 
acids (Figure 1.2). All amino acids except for glycine are chiral molecules that exist as D- and L- 
isomers. The naturally occurring amino acids incorporated into peptides and proteins are the L-
configuration. The amino acids side chain confers the different chemical, physical and structural 
properties of peptides and proteins.  
 
Figure 1.2  Proteogenic amino acids. Image created with ChemDraw. 
 
Amino acids polymerize with each other to form peptide bonds (Scheme 1.1). The amide bonds or 
peptide bonds are formed from a condensation reaction between the carboxylic acid moiety of one 
amino acid and the amino moiety of another amino acid, releasing a water molecule.5 This polymer 
3 
 
of amino acids or polypeptide joined by peptide bonds is the primary structure of protein. Many 
polypeptide has a free amino group at one end which is called the N-terminal. The other end is 
called the C-terminal and has a free carboxyl group. 
 
Scheme 1.1  Peptide bond formation. Image created with ChemDraw. 
There are four levels of protein structure: primary, secondary, tertiary and quaternary. While linear 
polypeptide chain makes up the primary structure of protein, the function of protein is dependent 
on its three-dimensional or tertiary structure. Hydrogen bonding between the oxygen of the C=O 
bond in the strand and the hydrogen of the N-H group form secondary protein structures such as α-
helix and β-sheet. The three-dimensional or tertiary structure is formed from bonding interactions, 
such as disulfide bridges, hydrogen bonds, ionic interactions and hydrophobic interaction between 
the side chain group. Depending on the sequence of amino acids, the secondary structures are folded 
into specific shape that results in a three-dimensional structure. The function of protein is directly 
dependent on its three-dimensional structure.6  
1.2 Solid Phase Peptide Synthesis  
Chemical synthesis of protein has enabled the control on protein composition beyond what can be 
accomplished by ribosome-mediated biosynthesis.7 It allows access to a wide diversity of complex 
protein such as posttranslational modification,8 fluorescence label, biotin tags and incorporation of 
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non-proteogenic amino acids with properties to study protein function and for biological studies of 
certain diseases. It is an efficient way to obtain enough pure material to study structure-activity 
relationships and perform structural determination of protein by NMR and X-ray crystallography.  
The methodology of solid phase peptide synthesis (SPPS), first described by R. Bruce Merrifield 
in 1963, has revolutionized the field of peptide chemistry.9 Chemical synthesis by solid phase 
peptide synthesis (SPPS) has become the major synthesis method used for the synthesis of peptides 
and small proteins. This chemistry on solid support is simple, fast and efficient when compare to 
the conventional methods in solution.9 SPPS is based on a scheme that involves a stepwise assembly 
of amino acid precursors to an insoluble support or resin (Scheme 1.2).10 Through a coupling 
reaction an amide bond is formed between two amino acids. The peptide is extended from the C to 
N terminus using protected amino acids. Prior to beginning the synthesis, the resin (solid support) 
is swollen using a synthetic solvent, such as DMF or DCM. Swelling allows the resins to expand 
and maximize exposure of the reactive function groups to react with the reactants.11 The synthesis 
starts by anchoring the first amino acid with the α-group and side chain protected to the resin via 
the carboxyl group. The alpha amino group on the attached amino acids is deprotected to make it 
accessible to react with the carboxyl group of a corresponding amino acid. The corresponding 
amino acid carboxyl group is activated using a coupling or activation reagent for the coupling 
reaction to occur. The synthesis is performed with an excess of amino acids, coupling reagents and 
base to drive the reaction to completion. Once the coupling reaction is completed, the resins is 
filtered and washed to remove excess reagents and byproducts. These alternating steps of α- amino 
deprotection, carbonyl activation coupling, and washing are repeated until the peptide of the desired 
size is formed. In the final step of the synthesis, the peptide is cleaved from the resin with all the 
side chain protective groups using a strong acid in the presence of scavengers to trap highly reactive 
carbocations formed during the cleavage procedure. The crude peptide in solution can easily be 
separated from the solid resin and purified by chromatographic techniques.  
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Scheme 1.2  Solid Phase Peptide Synthesis. Nα PG: Nα-protecting group, PG: side chain 
protecting group, Aa: amino acid. Image created with ChemDraw. 
There are two main strategies of SPPS (Figure 1.3), the Boc/benzyl and the Fmoc/tBu strategy.12 
The chemistries of these synthesis are defined by the two most widely used N-terminal protective 
groups, tert-butoxycarbonyl (Boc) and fluoren-9-ylmethyloxycarbonyl (Fmoc). In the Boc/benzyl 
strategy, the α-amino group is protected by the tert -butyloxycarbonyl (Boc) group and the side-
chain by benzyl-based protecting groups. In the Boc/benzyl strategy, the Boc group is removed by 
trifluoroacetic acid (TFA) in dichloromethane (DCM) while the semi-permanent side-chain 
protecting groups are removed by hydrogen fluoride (HF). In the Fmoc/tBu strategy based on an 
orthogonal concept, the α-amino group is protected by the base- labile Fmoc group and side- chain 
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functional groups by the acid-labile tert -butyl  or trityl-based protecting groups.13 The Fmoc group 
is removed by piperidine in N,N-dimethylformamide (DMF) or N-methylpyrrolidone (NMP) and 
the side chain protecting groups which compatible with base are removed by TFA. The Fmoc 
strategy of SPPS is the method of choice for peptide and protein synthesis since the deprotection is 
mild and compatible with modified peptides, such as phosphorylated and glycosylated peptides.14  
 
Figure 1.3  SPPS protection-group strategies. Image created with ChemDraw. 
Solid Support 
The proper selection of resin and linker is the most important factor for successful solid phase 
peptide synthesis. The protecting group, coupling reagents and cleavage conditions for the 
synthesis is dependent on the selection of the linker and resin. There are three group of resins used 
in SPPS, polystyrene (PS) based, poly ethylene glycol (PEG) grafted with polystyrene (PEG-PS), 
and PEG resins without polystyrene. Polystyrene (PS) resin used in 1963 by R. Bruce Merrifield 
for the synthesis of a tetrapeptide8 is the most common core resin used today for SPPS. PS resins is 
a hydrophobic matrix which is a copolymer of polystyrene crossed linked with 1% or 2% 
divinylbenzene (PS-DVB). These resins are insoluble in almost all common solvents. This feature 
allows the removal of excess materials and byproducts after each step of the synthesis by washing 
the beads.  Aprotic solvents such as dimethylformamide (DMF) and dichloromethane (DCM) are 
 
 
Boc chemistry Fmoc chemistry 
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commonly used to solvate and swell the resins. Swelling of the resin prior to the synthesis is 
important in solid phase synthesis since it allows the reagents to reach the active sites and the core 
of the resins. Resins that swell more have higher diffusion rate that result in shorter reaction time 
and more complete reaction. PS with 1% DVB is the most commonly used PS resin since the 
swelling factor is greater than 2% PS-DVB resins. Another factor that is important for high quality 
synthesis is the size of the resin. Two of the most commonly used resin sizes are beads with particle 
size distribution ranging from 75 – 150 µm (100 – 200 mesh) and 37 – 75 µm (200 – 400 mesh) in 
diameter. The reaction kinetics is faster when smaller beads size is used due to their higher surface 
area to volume ratio. Although PS resins are the most widely used resins for SPPS, the hydrophobic 
environment of these resin can amplify aggregational behavior of the peptide making the synthesis 
of large and highly aggregative peptides extremely difficult.  
To address the disadvantages of the hydrophobic PS resins, various hydrophilic resins such as 
polyethylene glycols (PEG) grafted PS gel-type resins and 100 % PEG resins has been developed. 
TentaGel ® resins (TG-resins) is a copolymer of low crossed linked PS on which PEG is grafted. 
.15 These resins more polar and have improved swelling properties in both polar and unpolar 
solvents, thus combining the useful features of both insoluble PS and soluble PEG support. 
ChemMatrix resin (CM) is a 100% PEG based resin that is used to prepare hydrophobic and highly 
structured peptides .16 
Resins are equipped with a bifunctional linker or handles that links the peptide to resins and allows 
elongate on the resins. Linkers provide control of the synthetic process, such as, functionalization 
of the C-terminal amino acid and the chemicals used during the reaction and cleavage of the peptide 
after synthesis from the resin.9 The most common linkers used for peptide syntheses using 
Fmoc/tBu chemistry are Wang resins and Rink resins. These linkers are acid labile and are cleaved 
using trifluoroacetic acid (TFA). Wang resin produces a peptide acid (COOH) and Rink resin 
produces a peptide amide (CONH2) after cleavage. 
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Coupling Reagents 
An important step in the solid phase peptide synthesis is the formation of the amide bond from the 
coupling reaction of the carboxyl group of an amino acid with the amino group of another amino 
acid. Although this reaction is thermodynamically favorable, the reaction is slow and requires a 
coupling reagent to transform the carboxy group into an active, more electrophilic species. The 
coupling reaction involves two steps, first activation of the carboxyl group by a coupling reagent 
followed by nucleophilic attack of the amino group on the other amino acid on the activated 
carbonyl (Figure 1.5). The most widely used coupling reagents are carbodiimides, aminium and 
phosphonium salts.17 N, Nʹ-dicyclohexylcarbodiimide (DCC) and N, Nʹ-diisopropylcarbodiimide 
(DIC) are commonly used in situ carbodiimides coupling reagents (Figure 1.4). Carbodiimides 
react with the carbonyl group to produce O-acylisourea, a super-active intermediate. This reactive 
intermediate reacts with another amino acid amine group to form a peptide bond. But O-acylisourea 
can undergo several undesired reactions such as rearranging to an inactive N-acylurea and 
cyclization to oxazolone. Oxazolone formation pathway causes racemization of the activated amino 
acid. This can be suppressed with the use of coupling additives such as 1-hydroxybenzotriazole 
derivatives. 1-hydrobenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt) are common 
triazoles additives used during carbodiimide coupling (Figure 1.4 and Figure 1.5).18 These additives 
react with carbonyl group to form an active ester that reduce the extent racemization and improve 
product yield.  
The uronium / aminium salts (HBTU, HATU, HCTU etc.) coupling reagents are based on HOAt / 
HOBt system (Figure 1.4).19 They react with carbonyl group to form OAt / OBt esters, which then 
react with an amino group on another amino acid. Phosphonium salts (BOP, PyBroP, PyBOP or 
BroP) are another family of coupling reagent based on the HOAt  /  HOBt system.20 Uronium / 
aminium and phosphonium salts do require the presence of a base in the reaction. 
Diisopropylethylamine (DIPEA) and N-methyl-morpholine (NMM) are the commonly used bases 
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in Fmoc SPPS. Recently, coupling reagents based on ethyl cyanohydroxyiminoacetate (Oxyma) 
was introduced.21 
 
Figure 1.4  Common coupling reagents. Image created with ChemDraw. 
 
Figure 1.5  Mechanism of DCC / HOBt coupling. Images adopted from BACHEM-http:// 
documents.bachem.com/coupling_reagents.pdf 
  
 
DCC 
HOBt 
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1.3 Native Chemical Ligation  
Native chemical Ligation (NCL) is one of the most important development in the synthesis of 
peptides and proteins.22 Kent and co-workers have revolutionized peptide synthesis by introducing 
NCL which has become the most popular method for connecting two unprotected polypeptide 
fragments through the formation of a covalent peptide bond. Synthesis of peptides greater than 50 
amino acids by SPPS alone often produce low purity product due to significant quantities of resin 
bond by-products formed after multiple coupling reaction, also coupling efficiency decreases as the 
length of the peptide increases. SPPS in conjunction with NCL addresses the limitations of SPPS 
and offer a powerful way to prepare peptides greater than 50 amino acid residues in length.23 The 
ligation strategy maintains the native peptide backbone which is important for peptide and protein 
bioactivity. It involves the reaction between a C-terminal peptide thioester with an N-terminal 
cysteine peptide to form a single polypeptide. In the first step of the reaction, a thioester containing 
fragment and a thiol undergo thiol-thioester exchange or a transthioesterification reaction to create 
an intermediate thioester containing peptide. Nucleophilic attack of the electron rich nitrogen from 
the α-amine on the ester carbonyl result in an S→N shift forming a native peptide bond (Scheme 
1.3).24 The technique allows for the incorporation of non-natural amino acids and post-translational 
modification(s) at a specific site in a protein in a controlled fashion. NCL is a regioselective and 
chemoselective reaction that joins a C-terminal thioester and N-terminal cysteine residue making 
the ligation site specific and efficient. Thus, the C-terminal peptide thioester is an important 
precursor for the reaction. Fmoc-SPPS strategy cannot be applied directly to synthesize C-terminal 
peptide thioester due to the lability of the thioester linkage to basic/nucleophilic conditions (20% 
piperidine/DMF). Presently, common methods used to synthesize peptide thioester by Fmoc SPPS 
approaches rely on the use of` special linkers, resins, handles and unnatural amino acids that require 
additional reaction steps. Examples of these methods include, the use of sulfonamide safety catch 
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linkers,25 N-acylurea linker,26 peptide hydrazides,27 a backbone pyroglutamyl imide linker28 and an 
activated N→S acyl transfer.29 
 
Scheme 1.3  Native Chemical Ligation. Image created with ChemDraw. 
1.4 Introduction to Peptide and Protein Modification 
1.4.1 Post Translations Modification. 
Protein synthesis in cells occurs through a process called translation.30 Following their synthesis, 
protein can undergo covalent modifications that introduce new functionality that can alter their 
structure and determine their biological function. These Post Translational Modifications (PTMs) 
play an important role in cellular processes such as regulating protein folding, cellular 
differentiation, gene expression, protein-protein interaction, protein degradation, signaling and 
regulatory processes.31 Identifying and understanding these PTMs is important in studying protein 
function in cells and in the treatment and prevention of diseases. These PMTs include 
Phosphorylation, Glycosylation, Acetylation, Ubiquitination, Lipidation, Methylation and 
proteolysis.32 Phosphorylation plays a critical role in regulating many cellular processes and is one 
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of the most studied PTM. It involves the covalent attachment of a phosphate group on serine, 
threonine or tyrosine residues. This modification introduces a conformation change in the protein 
by the phosphate group introducing a negative charge and hydrophilic group to the protein. In 
signaling, for example, kinase cascades are turned on and off by phosphorylation or 
dephosphorylation of a protein.33 Another example of PTM regulation is histone methylation. 
Methylation and demethylation of the histone protein by the addition and removal of one or more 
methyl groups to lysine or arginine residues is responsible for activating and suppressing gene 
expression.  
Chemical Modification of peptides and proteins 
Nature accomplished chemical modifications of protein through a range of Post Translations 
Modifications (PTMs). Beyond the scope of what nature does, chemist have developed tools to 
modify protein and further diversity its structure and function way beyond the human genome. 
Understanding the biomolecule at the molecular level is the goal of biologist and biochemist. 
Chemical modification of proteins provides a powerful tool to mimic natural PMTs of protein and 
offers a deep insight into understanding of their role in biological systems. Proteins are chemically 
modified by the covalent attachment of molecules (phosphorous group, PEG, drugs, probes etc.,) 
to amino acid side chains or the termini of the protein. These protein-synthetic molecule hybrids 
each have defined structure and function. Protein-fluorophore conjugate enables imaging analysis 
of the structure, dynamics and localization of the protein in the biological system.34 In drug 
development, attaching synthetic polymers (e.g., polyethylene glycol (PEG)) improve the 
pharmacokinetics of therapeutic proteins.35 Antibody-Drug Conjugate (ADC) generated by 
covalent modification of antibody with a potent cytotoxic compound or a small molecule drug can 
be used for efficient delivery of a payload to the target.36 
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The ideal modification strategy should have certain features for the protein to maintain structural 
integrity and homogeneity. The most challenging criteria is the need for the reaction to tolerate 
natural biological conditions, at or near neutral pH (pH 6 – 8), low to ambient temperature (≤37°C,), 
in an aqueous environment, and occur in the presence of multiple very reactive functionality. 
Despite the large number of strategies that have been developed so far, there remains a significant 
unmet challenge in both chemo-and regioselectivity of the reactions to modify a single amino acid 
or site in the presence of a sea of carboxylic acids, amines, alcohols and thiols. Over the past decade 
several site-specific modification strategies have been developed expanding the site-specific 
chemical modification toolbox. Example of these strategies include native protein-based specific 
modification, site directed mutagenesis to incorporate an unnatural amino acid, chemical 
introduction of a reactive handle, targeting the N-terminal and enzymatic modification. Chemical 
modification has also advanced beyond mono modification with the development of dual 
modification strategies for increasing protein functionalities in applications such as FRET 
experiments, targeted drug delivery and imaging.  
1.4.2 Modification of native amino acids.  
Lysine modification 
Lysine modification is the oldest and most widely used method for labeling protein via the primary 
amine group on the lysine side chain.37,38 Conventional lysine modification is non-selective since 
the amino acid is high in abundance39 and is surface exposed. The random modification of lysine 
residue generates a heterogenous mixture of conjugates and is often targeted when selective 
modification is not needed. Several methods exist for the modification of lysine. The nucleophilic 
amino group can be modified efficiently with N-hydroxysuccinimides (NHS) esters,40 
isothiocyanates, aldehydes, anhydrides, sulfonyl chloride, carbonates, fluorobenzenes, and 
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imidoesters (Figure 1.6a,b,c,d). Site-selective modification cannot be accomplished by these 
methods since they can also modify other nucleophilic side chains and the N-terminal amine. 
Recently more selective lysine modification methods have been developed such as modification 
based on rapid 6π-aza-electrocyclization reaction reported by Tanaka and Fukase (Figure 1.6e)41 
and modification based on coupling with diazonium terephthalate reagents reported by Carreira 
and coworkers (Figure 1.6g).42 Also, a method to modify a single lysine residue under 
biocompatible using computer assisted design of sulfonyl acrylate was recently reported (Figure 
1.6f).43 
 
Figure 1.6  Common methods for modification of lysine residue. Image created with ChemDraw. 
Cysteine modification 
Cysteine low natural abundance39and highly nucleophilic character makes it a very attractive target 
for site-selective protein modification. Most cysteine residues in proteins are oxidized in disulfide 
bonds for protein structure stability. Because of its strong and robust nucleophilic side chain, like 
lysine, cysteine residues have been widely used for modification of proteins. The nucleophilic 
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sulfhydryl side chain reacts rapidly with electrophiles, such as α-halocarbonyls, aminoethylhalides, 
disulfides and Michael acceptors for protein modification.44 The oldest and most common methods 
are alkylation with widely used Michael acceptors such as maleimide and vinyl sulfones (Figure 
1.7a) and alkylhalides such as iodoacetamide (Figure 1.7b). Cysteine residues also naturally modify 
itself via formation of disulfide bonds.44 In addition to these classical nonselective modification 
approaches, methods have been developed to modify a single site -directed mutagenesis introduced 
cysteine residue on the protein for site-specific protein modification. Cysteine low abundance in 
combination with site directed mutagenesis can generate a protein construct with a single cysteine 
for site-specific modification. The amino acid can also be converted to dehydroalanine (Dha) to 
introduce an electrophilic handle that can be functionalized through Michael addition of thiol 
reagents. Although site -directed mutagenesis of cysteine has become a popular method for site-
specific modification, this modification strategy is incompatible with protein that rely on cysteine 
for catalytic function, protein folding or structural stability.  
 
Figure 1.7  Common methods for modification of cysteine residue. Image created with ChemDraw. 
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Aromatic amino acid modifications 
To address the limitations of lysine and cysteine for site-selective modification of  native amino 
acids, several methods have been developed to target the aromatic amino acids. These methods 
took advantage of the low to intermediate frequency of these residues on protein surface to achieve 
higher selectivity and an attractive target for selective modification. Tyrosine is an attractive amino 
acid for site selective modification because abundance is less than lysine on the surface of proteins. 
Strategies have been developed to selectively modify the phenolic hydroxy group on the tyrosine 
residue. Tyrosine can be selectively modified by a three-component Mannich-type reaction (Figure 
1.8a)45,46, the use of diazonium salts (Figure 1.8b),47,48 alkylation using π-Allypalladium 
complexes49 and a click-like ene-type reaction with cyclic diazodicarboxamide reagents (Figure 
1.8c).50 Recent work has also demonstrated site-selective modification of tyrosine residue by an 
electrochemical strategy with phenothiazine derivatives51 and azo coupling with aryl diazonium 
salts.52 
 
Figure 1.8  Common methods for modification of tyrosine residue. Image created with ChemDraw. 
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Tryptophan has been targeted for site- specific modification since it is the least abundant of the 20 
naturally occurring amino acid. It is likely to be found in the hydrophobic core of the protein and 
it is included in the primary sequence of 90% of proteins. Several methods have been developed 
for modification of the indole C2 position on the amino acid side chain. Tryptophan residues can 
be modified by transition metal-catalyzed reaction with rhodium carbenoids (Figure 1.9a)53, 
transient metal-free method based on organoradicals (Figure 1.9b).54 Recently site selective 
tryptophan modification method by C – H activation under mild condition using an aryl-diazonium 
with PdNP nanohybrids catalyst was developed (Figure 1.9c).55 
 
 
Figure 1.9  Common methods for modification of tryptophan residue. Image created with 
ChemDraw. 
Modification of native amino acids has the advantage that they are easily accessible for 
modification without the need for special techniques. However, high abundance natural amino 
acids (e.g., lysine) severely limits the site selectivity of reactions targeting this residue. These 
modification strategies are useful when selectivity is not needed for example displaying multiple 
antigen in conjugated vaccine. Since reactivity is dependent on the accessibility of the amino acid 
side chain, modification of low abundance amino often have slow kinetics and may require a 
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catalyst, high concentration of the reactants and unfavorable reaction conditions for the reaction to 
occur. Because of these limitations, modification of native protein by site-specific and residue-
selective approaches remain challenging. 
1.4.3 Incorporation and Modification of unnatural amino acids 
Modification of protein at a specific amino acid residue at a specific location on the protein can be 
accomplished by the introduction of unnatural amino acids with extrinsic functionalities into 
protein. Targeting an unnatural amino acid for modification addresses the issues of selectivity that 
exist with modification of native amino acids and it is amongst the most successful method to 
achieve selective and site-specific modification. Several different approaches have been used to 
incorporate unnatural amino acids. The most common approach is a two-step approach that requires 
the introduction of the unnatural amino acid with a unique reactive handle or a biorthogonal 
reporter, followed by modification of the biomolecule using a biorthogonal reaction. Biosynthetic 
methods for incorporating an unnatural amino acid at a desired position in the protein utilizes a 
modified translational machinery via a stop codon by an orthogonal tRNA/aminoacyl-tRNA 
synthetase pair.56,57 This incorporation of a biorthogonal functional groups (e.g., azide, alkynes, 
alkene, tetrazine, aldehydes, or ketones) generates a unique reactive handle on the protein for site-
specific modification. Because several new biorthogonal reactions have been developed to target 
these non-biological functional groups, this strategy is now widely used for site-specific protein 
modification. Unnatural amino acids bearing an azide functionality can react with alkynes in the 
Cu(I) catalyzed azide-alkyne cycloaddition (CuAAC) reaction described in 2001 by Sharpless as 
“Click Chemistry” (Figure 1.10a).58,59 Due to cell toxicity of copper ion, the biocompatibility of 
CuAAC reaction has been improved by the development of strain-promoted azide-alkyne 
cycloaddition (SPAAC) (Figure 1.10b).60 Azides also reacts with triarylphosphines in Staudinger 
ligation, the first reported biorthogonal chemistry reaction, developed by Bertozzi and co-workers 
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in 2000 (Figure 1.10c).61,62 Traceless Staudinger ligation was developed to introduced the amide 
bond between azide and alkyne without an intervening triarylphosphine (Figure 1.10d). Genetic 
encoded carbonyl functionalities such as ketones and aldehydes can be modified with hydrazines 
and hydroxylamine/aminooxy reagents to form stable hydrazone and oxime bonds (Figure 1.10e). 
Although these reactions have made tremendous scientific impact by providing a solution to 
selective functionalization there are limitations, the incorporation of unnatural amino acids requires 
protein engineer that can disrupt protein expression and function. Also, the incorporation of 
unnatural amino acid is a very challenging task. Carbonyl reactions are generally favored in acidic 
conditions and have slow kinetics that may require the use of catalyst. 
 
Figure 1.10  Common methods for unnatural amino acid modification. Image created with 
ChemDraw 
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1.4.4 Chemical Modification of Peptides and Proteins N-terminal  
Complementing the reactions discussed so far for site-specific modification such as modification 
of artificial induced cysteine and unnatural amino acids, a number of methods for site- specific 
modification the protein N-terminal have been developed. The N-terminal provide a unique reactive 
site for site-specific modification since there is only one such group in a single -chain peptide or 
protein. The terminal amino acid can modify directly or is converted to a unique functional group 
handle for further modification.  
pH-controlled N-terminal Modification 
Site- Selective modification of the N-terminal amine can be accomplished through judicious control 
of the reaction pH. The basicity of the N-terminal α-amine (pKa ~8) is lower than the ε-amine (pKa 
~10.5) on the side chain of lysine as a result of the inductive effect of the nearby carbonyl.63 This 
difference in the pKa allows for selective modification such as acylation and alkylation of the α-
amine when the reaction is performed at low-to-neutral pH. At low to physiological pH, the N -
terminal α-amine will be charged and solvent exposed. At slightly basic pH it will be deprotonated 
and more nucleophilic than those in lysine residues. The α-amine group can react with esters (N-
Hydroxysuccinimide (NHS)) (Figure 1.11a), aldehydes followed by reduction (Figure 1.11b)64, 
ketene (Figure 1.11c)65 and imidazole-1-sulfonyl azide for azide incoperation66 at controlled pH for 
site-specific modification. However, complete site specificity is rarely achieved with these methods 
due to the presence of a high abundance of competing lysine residues and the fact that their pKa 
can be lower due to the local environment. 
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Figure 1.11  Common methods for pH-controlled N-terminal Modification. Image created with 
ChemDraw 
Modification of specific residues at the N-terminal 
The N-terminal α-amine can react in combination with the side chain of specific amino acid residing 
at the N-terminal through the formation of cyclic intermediate and product for selective 
modification. Cysteine, serine, threonine and tryptophan residues side chains in combination with 
α-amine at the N-terminal can condense with aldehydes for site selective modification (Figure 
1.12a,b,d).67-69 N-terminal cysteine residue can react chemoselectively with thioesters through 
Native Chemical Ligation (NCL) discussed in section 1.3 for site-selective modification (Figure 
1.12c).70 The N-terminal α-amine of specific amino acid residues can also be modified by a twostep 
strategy to generate a unique reactive handle which can be further modified for N-terminal 
modification.71 Aldehydes handles can be installed at the N-terminal via oxidative cleavage of 
serine and threonine residues for further selective modification with amines and alkoxyamine 
groups.72  
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Figure 1.12  Common methods of residue specific modification. Image created with ChemDraw. 
Modification of  N-terminal amine 
Oxidation of the N-terminal amine by transamination reaction with pyridoxal 5ʹ -phosphate 
(PLP)73,74 or Rapport salt75 can also generate reactive ketone or aldehyde handles for further site-
specific modification of peptides and proteins (Figure 1.13a). Aldehyde or ketone can react with 
hydrazines and alkoxyamine reagents for site-specific modification. We recently reported a direct 
aldol coupling reaction using amino-acid-derived organocatalysts to modify N-terminal aldehyde.76 
N-Terminal amine can be modified directly without interfering with the side chain group. N-
terminal residues can be modified through the oxidative coupling of o‐aminophenols and anilines 
with ferricyanide (Figure 1.13b).77a Francis and coworkers also reported direct modification of N-
terminal residues on peptides and N-terminal proline residues on proteins using oxidative coupling 
with potassium ferricyanide and o-aminophenols (Figure 1.13d).77b Another method reported by 
Francis and coworkers for direct modification of the N-terminal residues using 2-pyridine carboxy 
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aldehyde (2-PCA) through the formation of an imidazole ring (Figure 1.13c).78 However, these 
reactions are specific for the N- terminal amine but are not residue specific since they will modify 
any amino acid residue at the N-terminal.  
 
Figure 1.13  Common methods N-terminal amine modification. Image created with ChemDraw. 
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1.5 Applications of chemical modification 
Methods for site-selective modification of proteins are in high demand for the chemical synthesis 
of modified proteins to study Post Translation Modification as well as for applications in chemical 
biology, biosensors, biotherapeutics (e.g., PEGylation, lipidation, and antibody–drug conjugates), 
bioimaging, medical diagnostics, and material sciences.79 
To study post translation modification. 
Post translation modification (PTM) of protein modulates protein function in various biological 
processes. Elucidating the effect of these modification on protein function is critical in 
understanding their functional significance and for the development of new drug targets. Access to 
homogenous samples of post post-translationally modified protein in multi-milligram quantities are 
critical for probing protein structure/function relationships and protein/protein interactions. Native 
Chemical Ligation (NCL) is one approach used to prepare post-translationally modified protein 
with high precision for the modification site. In this strategy, peptides are synthesized with intact 
modification by Solid Phase Peptide Synthesis, joined to the protein post synthesis through NCL 
and fold in vitro to give the desired modified protein. Phosphorylation is a common post translation 
modification that regulates several kinases and phosphatases in the human proteome. Since 
abnormal phosphorylation is responsible for a number of diseases, understanding the regulatory 
mechanisms of kinases and phosphatases is critical for developing new drug. 
Chemical modification uses in Proteomic and Bioimaging.  
Chemical modification reactions serve multiple purposes in proteomics and imaging. The covalent 
attachment of various molecules (probes) to a protein can be used to display various functionalities, 
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which can be used for detection, purification, or modulating the function of the protein (Figure 
1.14).80,81 Reduction and alkylation of the thiol on cysteine is used in the preparation of proteomic 
samples for analysis by mass spectrometry.82 Covalently attaching a fluorophore to a protein allows 
for monitoring of a fluorescent signal and provide insight into the protein localization within cells 
or protein identification using SDS-PAGE.83 More advanced fluorescence-based assays such as 
fluorescence/Förster resonance energy transfer (FRET) can measure protein–protein interactions 
or conformation changes. Biotinylated protein can be used in protein purification by binding to 
streptavidin resins.80 Attachment of radiolabel to protein allows for monitor in vivo distribution of 
protein by positron emission tomography (PET).84 
 
Figure 1.14  Chemical modification use in Proteomic. Image created with ChemDraw. 
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To improve the properties of therapeutic proteins.  
Therapeutic protein is a rapidly growing therapeutic agent due to the success in the treatment of 
challenging diseases such as cancer, diabetes, hemophilia, arthritis and other autoimmune diseases. 
One significant limitation in the use of protein based therapeutics is the rapid degradation and 
excretion from the patient. This results in decrease in the drug half-life, increase the chance of 
immunological response, require more frequent dosing and decrease patient compliance. One 
strategy used to address this limitation is covalent attachment of propylene glycol (PEG) to the 
therapeutic protein (Figure 1.15).85 PEG shields the antigenic epitopes on the protein, reduces 
degradation by proteolytic enzymes, increases its hydrodynamic size and increase circulatory 
lifetime by decreasing renal clearance (Figure 1.15). Modified therapeutic proteins with PEG 
significantly improved pharmacokinetic / pharmacodynamic properties compared to the 
unmodified proteins. Most of the approved PEGylated protein were synthesized by non-specific 
modification chemistries resulting in a heterogenous mixtures of conjugates. For example, 
PEGASYS (peginterferon alfa-2a) a Hoffmann–La Roche drug approved in 2002 for the treatment 
chronic hepatitis C, consists of a PEGylated interferon alfa-2a.86 The PEG is attached covalently to 
interferon alfa-2a at lysine side chains through a stable amide bond. As a result, the thrice-weekly 
administration schedule of interferon alfa-2a was reduced to a once-weekly administration of 
PEGASYS®.  
Site-selective PEGylation has been a useful strategy to attach the PEG molecule at a specific amino 
in proteins. Pegfilgrastin marketed under the brand name Neulasta® is a PEGylated protein used 
in the treatment of neutropenia and its associated infections caused by chemotherapy or bone 
marrow transplantation where the PEG chain has been introduced in a site-specific manner.87 The 
protein was conjugated using a PEG–aldehyde molecule, where the aldehyde group was used for 
reductive amination of the N-terminal amine. Cimzia® (certolizumab pegol), a PEGylated anti-
TNF therapeutic monoclonal antibody Fab fragment drug used for the treatment of Crohn's disease 
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and rheumatoid arthritis, approved for use in 2008 and 2009, respectively is another example of 
site-selective PEGylation of therapeutic protein.88 The protein is PEGylated through a C-terminal 
engineered cysteine reaction with maleimide. There are currently 12 approved PEGylation 
biotherapeutics and many potential products in development. Although initial PEGylation was 
mainly random, the success of Neulasta® and Cimzia® together with problems of non-specific 
PEGylation, there is great need for site-specific chemistries for protein PEGylation.  
 
Figure 1.15 PEGylated Protein. Image created with ChemDraw. 
Antibody Drug Conjugates 
Antibody-Drug Conjugates (ADCs) is one of the fastest growing and most promising classes of 
oncology drugs. Unlike conventional cancer therapy that damage healthy tissues, ADCs combines 
the high affinity and specificity of antibodies for cell surface antigen with the potency and high 
penetrating power of small molecule drugs for targeted delivery and induce apoptosis. ADCs 
consist of a recombinant monoclonal antibodies (mAbs) with a covalently attached cytotoxic drug 
through a chemical linker. The linker allows for release of the drug once it is inside the cancer cells. 
Most of cytotoxic drugs used for ADCs are DNA damaging agent (e.g., calicheamicin) or 
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microtubule-disrupting agent  (e.g., auristatins). ADC works by the antibody carrying the cytotoxic 
drug binding to specific antigens that are uniquely expressed or overexpressed on the cancer cells. 
Once the ADC binds to the antigen, it internalized into lysosomes and releases the potent cytotoxic 
drug through enzymatic cleavage or disulfide reduction. The cytotoxic drug diffuses into the 
cytoplasm for cytotoxicity and apoptosis (Figure 1.16).89 Currently, four ADCs have being 
approved by the FDA for the treatment of cancer: gemtuzumab ozogamicin (Mylotarg™) is an anti-
CD33 ADC used for the treated of acute myeloid leukemia;90 brentuximab vedotin (Adcetris®) an 
anti-CD30 ADC for the treatment Hodgkin's lymphoma and systemic anaplastic large cell 
lymphoma (ALCL);91 ado-trastuzumab emtansine (Kadcyla®) an anti-human epidermal growth 
factor receptor-2 (HER2) ADC for the treatment of metastatic breast cancer92 and inotuzumab 
ozogamicin (Besponsa®) an anti-CD22 ADC for the treatment acute lymphoblastic leukemia 
(ALL). To date, the approaches used to prepare ADCs are conventional methods that generates a 
heterogenous mixture of conjugates with different drug-to-antibody ratios (DAR) and different 
pharmacokinetics properties. The random conjugation strategies make characterization of the 
conjugated drug difficult. Mylotarg™ used NHS ester conjugation at random lysine residues to 
attach calicheamicin through a cleavable hydrazone linker to humanized immunoglobulin G4 
(IgG4) mAb specific for CD33.90 Kadcyla ® also use random lysine conjugation strategy to attach 
maytansinoid (DM1), a  microtubule-disrupting agent, to humanized IgG1 mAb via non-cleavable 
thioether linkers. Maleimide conjugation at cysteine residues was used for ADC Acdetris® to 
conjugate 4 monomethyl auristatin E (MMAE) through a protease cleavable linker to chimeric 
IgG1 mAb specific for CD30. The most recently approved ADC, Besponsa®, used lysine 
conjugation to conjugate calicheamicin derivatives to inotuzumab. The conjugation process used a 
surfactant to control the number of lysine residues conjugated.93 
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 To improve the conventional conjugations approaches used to prepare ADCs, a number of site-
specific strategies are in development. For example, THIOMABTM antibody technology that uses 
site-directed mutagenesis to incorporate engineered cysteine residues for ADC synthesis.94 
 
Figure 1.16  Mechanism for drug delivery by ADC.89 Image adopted with permission. 
1.6 Thesis Aim 
The work described in this thesis aimed at achieving two goals: (1) to develop a novel cyclic 
urethane technique for the direct synthesis of peptide thioester on solid support by Fmoc-based 
chemistry for NCL. Peptide thioester reacts in a chemoselective and regioselective manner with N-
terminal cysteine peptides via NCL for chemical protein synthesis and C-terminal residue-specific 
modifications. Chapter 2 of this thesis describes the experiments conducted to develop a simple 
and versatile method for the synthesis of peptide thioester using Fmoc-based chemistry. The 
resulting thioester is free of epimerization and is successfully applied for the assembly of a synthetic 
bioactive peptide and synthesis of longer peptides by using NCL. The synthesis of peptide thioester 
using Fmoc chemistry SPPS in combination with NCL is compatible for the synthesis of peptides 
and proteins with a wide diversity post-translational modifications (PTM).  
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(2) the second aim is to develop a residue-specific bioconjugation strategy to selectively modify 
peptides and proteins at a single amino acid at a single location. Chapter 3 describes the studies 
carried out to develop a Secondary Amine Selective Petasis (SASP) bioconjugation reaction for 
selective modification of N-terminal proline and secondary amines. The reaction was applied to 
selectively dually modified N-terminal proline on unprotected peptide and protein under 
physiological conditions. SASP is a useful strategy that can be used generate a variety of conjugates 
efficiently, regioselectively, chemoselectively, and stereoselectively. Selectivity of the reaction for 
secondary amine also provide a useful tool to study post-translational modifications (PTM) such as 
mono methylated lysine. 
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Chapter 2 
Serine Promoted Synthesis of Peptide Thioester-Precursor on Solid 
Support for Native Chemical Ligation 
2.1 Abstract 
C-terminal peptide thioesters are important precursors for the synthesis of peptides and proteins via 
native chemical ligation. Fmoc-solid phase peptide synthesis of peptide thioesters for native 
chemical ligation is a challenge. We have developed of a simple and versatile approach for direct 
synthesis of peptide thioesters from solid support utilizing Fmoc based chemistry. Peptide 
thioesters synthesis is generated from formation of a cyclic urethane moiety via a selective reaction 
of the backbone amide chain with the side chain of serine. The activated cyclic urethane moiety 
undergoes rapid displacement by a thiol to generate the thioester in solution directly from the solid 
support. Since the method activates serine for the synthesis of thioester it is independent of the type 
of resins, linkers, handles, and unnatural amino acids typically needed for synthesis of peptide 
thioesters using Fmoc chemistry. The resulting thioester is free of epimerization and the 
applicability of the method was demonstrated for the synthesis of longer peptides by using NCL.  
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Graphical Abstract 
 
Figure 2.1  Graphical abstract for Serine promoted synthesis of peptide thioester-precursor on solid 
support for native chemical ligation. Reprinted with permission from reference 1 
2.2 Chapter Objective  
This chapter describes the develop of a simple and robust method to synthesize peptide thioester 
directly from solid support using Fmoc based SPPS. Methods developed so far for the synthesis of 
peptide thioester using Fmoc chemistry require special linkers, resins, additional reactions and are 
time-consuming. We envisioned utilizing a natural serine residue that can be assembled on the solid 
support using Fmoc chemistry to generate the peptide thioester for NCL. We hypothesised that  
selective activation of the amide bond at the unprotected serine residue will generate a five 
membered cyclic urethane moiety that will serve as a thioester-precursor on solid support.  
Nucleophilic displacement of the cyclic urethane moiety by a thiol will release the thioester in 
solution for use in NCL. We tested proposed methodology by first optimizing the formation of the 
cyclic urethane moiety. The optimized reaction for the synthesis of cyclic urethane- activated 
peptides was demonstrated on peptides attached to different resins, with different protecting groups 
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and amino acid sequence. We then investigated potential epimerization during the synthesis of 
cyclic urethane- activated peptides reaction and the thiolysis reaction. The thioesterication 
technique was evaluated using different using peptide with different amino acid sequences. Finally, 
we demonstrated this methodology to synthesize a long peptide thioester by NCL.  
2.3 Introduction 
Total chemical synthesis of proteins provides easy access to various modified proteins with high 
stability and improved biological activity which can be key in understanding the importance of 
various post translational modifications.2,3 Native Chemical Ligation (NCL) has revolutionized the 
field of chemical synthesis of proteins. It relies on the chemoselective reaction between a peptide 
thioester and a cysteinyl peptide.4 Thus, considerable effort has been applied for synthesis of 
peptide thioesters using Fmoc or Boc solid-phase peptide synthesis (SPPS) approach.  
While peptide thioesters can be prepared by Boc-chemistry SPPS in a simple manner by installing 
a thioester linkage to a resin, synthesis of peptide thioester by Fmoc-based methods is compromised 
by the incompatibility of the thioester against piperdine which results in thioester cleavage during 
the Fmoc deprotection. However, the use of Boc chemistry is limited by the required use of hydrogen 
fluoride (HF) for Boc deprotection and incompatibility for synthesis of post translationally modified 
peptides such as glyco- or phospho-peptides.5. Thus, substantial efforts have been utilized for the 
synthesis of peptide thioesters by Fmoc SPPS approach ,such as, the use of less basic Fmoc 
deprotection protocol,6 use of sulfonamide safety catch linkers,7 activation of protected peptides in 
solution,8 O/N to S acyl shift methods,9-15 and peptide hydrazides.16-18 The activation of protected 
peptides in solution for synthesis of thioesters is limited by the susceptibility of C-terminal residue 
to racemization.8 Despite the significant advances of O/N to S acyl shift methods, they are limited 
by slow ligation kinetics,15 and requirement of unnatural linkers.14,15 Synthesis of peptide thioesters 
via peptide hydrazides require acidic conditions,15 which is unsuitable for synthesis of acid sensitive 
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post translationally modified peptides. 
One promising approach for the formation of thioester is the activation of a relatively inert 
backbone amide bond followed by subsequent thiolysis. Examples include, an activated N-acylurea 
linker,19, 20 and a backbone pyroglutamyl imide linker.21 The activated N-acylurea approach has 
been extensively applied the for synthesis of a variety of proteins19, 20 but is limited by the use of 
unnatural amino acid, formation of various side products,22, 23 and requirement of additional steps 
for the synthesis of N-methylated unnatural amino acid.20 Whereas, a backbone pyroglutamyl imide 
linkers are limited by the instability of the resin.21 Thus, simple and versatile route to peptide 
thioesters via Fmoc-SPPS is highly desirable.  
We have developed an alternative approach for the synthesis of Fmoc based SPPS peptide 
thioesters to overcomes some of the challenges associated with existing methods. The significance 
of this approach which makes it distinct from the currently used methods, is that it utilizes natural 
serine residue and does not require any special unnatural amino acids and loading procedures.19, 20  
The approach relied on the selective activation of the back-bone amide bond at the C-terminal 
serine residue for generation of a cyclic urethane moiety on a solid support. The synthesis of peptide 
thioesters by this strategy entails the anchoring of a C-terminal serine residue with a selectively 
removable side-chain protecting group to a solid support (Scheme 2.1). After chain assembly, the 
side-chain of serine was deprotected and activated by an electrophile, resulting in the formation of 
a cyclic urethane moiety on the resin (Scheme 2.1). We have reported a method for the selective 
cleavage of peptide bonds in solution for protein sequencing by employing the backbone amide 
activation strategy.24 Next, nucleophilic displacement of the cyclic urethane moiety by treatment 
with a thiol released the peptide thioester from the solid support, which was then be deprotected in 
solution (Scheme 1). This approach utilizes serine during chain assembly followed by acylation of 
the backbone amide chain and is compatible with various amino acids and protective groups 
commonly utilized in Fmoc SPPS. Moreover, the thioester is directly obtained from solid support, 
thus reducing the need for extra steps before proceeding with NCL, which is in contrast with 
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traditional methods. Peptide thioester synthesised by this method is compatibility for synthesis of 
a variety of post translationally modified peptides by NCL. 
 
Scheme 2.1  Rationale for the activation of serine to cyclic urethane moiety for the synthesis of 
peptide thioesters and its application in native chemical ligation for chemical synthesis of proteins. 
Reprinted with permission from reference 1. 
2.4 Results and Discussion 
2.4.1 Synthesis of the cyclic urethane moiety 
To test our proposed methodology for the synthesis of thioesters, the first step was the synthesis of 
the cyclic urethane moiety from serine residue on solid support. To optimize the formation of the 
cyclic urethane moiety on solid support, a model hexapeptide Ac-GGSAAG was assembled on 
solid support and the trt group was selectively deprotected from the C-terminal using TFA : DCM 
(1:3). For the activation of the side chain of serine, various electrophilic reagents such as 4-
nitrophenyl chloroformate, 1,1'-Carbonyldiimidazole (CDI) and N, N’-disuccinimidyl carbonate 
(DSC) were screened (entries 1-4, Table 2.1). Quantitative conversion of peptide Ac-GGSAAG 1a 
to cyclic urethane moiety Ac-GGOxdAAG 2a was observed by using DSC as an electrophile (entry 
4, Table 2.1). The conversion yields were calculated from the HPLC data. The formation of the 
cyclic urethane moiety was confirmed by LCMS and NMR spectroscopy. 
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Table 2.1  Screening of different reagents for the activation of backbone amide chain at serine.a 
 
 
 
Entry Reagent Additive Conv. (%) b 
1 4-nitrophenyl chloroformate - 0 
2 4-nitrophenyl chloroformate DMAP 20 
3 CDI DMAP 60 
4 DSC DMAP 99 
 
aReaction conditions: To a peptide Ac-GGSAAG 1a on solid support (25 mg, 0.52 mm/g), a 
solution of 4-nitrophenylchloroformate/CDI/DSC (35 mg), DIEA (23 µL) and DMAP (catalytic 
amount) in DMF (3 mL) was added and the resin was left on a shaker overnight (ON) at room 
temperature (RT). bConversion to Ac-GGOxdAAG 2a was calculated from the absorbance at 
220 nm using HPLC. Reprinted with permission from reference 1. 
2.4.2 Optimization of the reaction conditions for the formation of cyclic urethane moiety 
on solid support. 
To further optimize the formation of the cyclic urethane moiety on solid support, various other 
reaction conditions such as solvent, time, temperature, and equivalent of reagents were explored on 
a model peptide, Fmoc-ASF-Rink AM 1b (entries 1-6, Table 2.2). The low conversion to activated 
peptide 2b (40%) in DCM is due to the poor solubility of DSC in DCM (entry 1, Table 2.2). When 
a mixture of DCM : DMF (1:1) was used as a solvent, conversion % to 2b increased from 40 to 60 
%, whereas when the reaction was performed in DMF, the conversion % increased to 99% (entries 
2-3, Table 2.2). This is due to the high solubility of DSC in DMF. 
Next, to determine the role of N-terminal protecting group (Pg) in the formation of cyclic urethane 
moiety, a model peptide Pg-ASF-Rink AM with other N-terminal protective groups such as acetyl, 
tosyl, and Boc were investigated (entries 7-9, Table 2.2). Contrary to earlier studies,25 the results 
indicated that the formation of the cyclic urethane moiety from serine by activating the backbone 
peptide chain is independent of the nature of the N-terminal protecting group.  
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Table 2.2  Optimization of the reaction conditions for the formation of cyclic urethane moiety 
on solid support.a  
 
 
 
 
 
Entry Protective 
Group 
DSC (Equiv.) Solvent Time (h) Conv. (%)b 
1 1b Fmoc 10 DCM 17 40 
2 1b Fmoc 10 DCM : DMF 17 60 
3 1b Fmoc 10 DMF 17 >99 
4 1b Fmoc 5 DMF 17 70 
5 1b Fmoc 10 DMF 3 30 
6 1b Fmoc 10 DMF 7 90 
7     1c Ac 10 DMF 17 >99 
8 1d Tosyl 10 DMF 17 >99 
9 1e Boc 10 DMF 17 >99 
 
aReaction conditions: Peptide 1 (25 mg, 0.87 mm/g) on solid support was reacted with DSC (5-
10 equiv.), DIEA (5-10 equiv.), and a crystal of DMAP in different solvents (3 mL) at room 
temperature for 3-17 h. bConversion to cyclic urethane moiety 2 was calculated from the 
absorbance at 220 nm using HPLC. Reprinted with permission from reference 1. 
2.4.3 Exploring the reaction with various peptides with different sequences. 
Next, the serine activation reaction was explored on solid support with various peptides with 
different sequences (Table 2.3). The results showed that the formation of the activated cyclic 
urethane moiety is independent of the nature of the amino acid preceding serine, and high 
conversion to cyclic urethane moiety was obtained even with bulky amino acid residues 
neighbouring serine (Table 2.3). Moreover, results in Tables 2.1, 2.2 and 2.3 showed that activation 
of serine does not depend upon the relative position of serine and the resin.  
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Table 2.3  Substrate scope of serine cyclization on Fmoc-Gly-Xaa-Ser-Phe-Ala-Gly.a  
 
 
 
 
 
Substrate Xaa Conv. (%) b 
1a’ Ala >99 
1b’ Gly >99 
1c’ Met >99 
1d’ His  >99 
1e’ Tyr >99 
1f’ Trp >99 
1g’ Val >99 
   
aReaction conditions: Peptide 1ʹ (25 mg, 0.7 mm/g) on solid support was reacted with DSC (10 
equiv.), DIEA (10 equiv.), and a crystal of DMAP in DMF (3 mL) at room temperature for 17 h. 
bConversion to cyclic urethane moiety 2ʹ was calculated from the absorbance at 220 nm using 
HPLC.  
2.4.4 Stability and epimerization studies during the formation of cyclic urethane moiety. 
To evaluate the stability of the cyclic urethane moiety on the resin bound peptide, the peptide was 
stored in a desiccator for longer than a month. The resin-bound cyclic urethane moiety was found 
to be very stable in a desiccator for longer than a month, which is in contrast to previously reported 
pyroglutamyl imide method.21 Epimerization studies were performed during the formation of the 
cyclic urethane moiety for peptide Fmoc-GFA(L) Oxd(2f) and corresponding diastereoisomer 
Fmoc-GFA(D)Oxd (2fʹ). Results showed the formation of the cyclic-urethane moiety on peptide 
Fmoc-GFA(L)Oxd (2f) and corresponding diastereoisomer Fmoc-GFA(D)Oxd (2fʹ) showed no 
sign of epimerization as determined by HPLC (Figure 2.1). 
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Figure 2.2  HPLC traces of (a) purified cyclic urethane activated peptide 2f Fmoc-GFA(L)-Oxd 
(b) purified cyclic urethane activated peptide diastereoisomer 2fʹ Fmoc-GFA(D)-Oxd and (c) 
mixture containing both diastereoisomers of cyclic urethane activated peptides 2f and 2fʹ, 
demonstrating lack of detectable epimerization. Reprinted with permission reference 1. 
Since we hypothesized that peptide with bulky phenyl group neighboring serine might be more 
prone to epimerization,  studies on peptide with bulky phe residue was investigated during the 
formation of cyclic urethane moiety for peptide Fmoc-GVALF(L)-Oxd 2j and epimer Fmoc-
GVALF(D)-Oxd 2jʹ (Scheme 2.2). Again, the formation of the cyclic-urethane moiety on peptide 
Fmoc-GVALF(L)-Oxd (2j) and corresponding diastereoisomer Fmoc-GVALF(D)-Oxd (2j’) also 
showed no sign of epimerization as determined by HPLC (Spectra 2.1 – 2.3). 
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Scheme 2.2  Synthesis of Fmoc-GVALF(L)-Oxd and epimer Fmoc-GVALF(D)-Oxd on solid 
support. 
 
Spectra 2.1  HPLC and MS of purified activated peptide diastereoisomer Fmoc-GVALF(D)-Oxd  
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Spectra 2.2  HPLC and MS of purified activated peptide diastereoisomer Fmoc-GVALF(L)-Oxd  
 
Spectra 2.3  HPLC of mixture containing both diastereoisomers of activated peptides Fmoc-
GVALF(L)-Oxd and Fmoc-GVALF(D)-Oxd 
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2.4.5 Thiolysis Reaction – Synthesis of Peptide Thioester in solution. 
After activating the peptide backbone to form a cyclic urethane moiety on a model peptide Ac-
GPMLA-Oxd-Rink AM (2g) on solid support, the thiolysis reaction was performed (Table 2.4). 
The resin was treated with varying amounts of thiol/base mixtures and solvents at different 
temperatures, in order to release the peptide thioester Ac-GPMLA-COSR 3g into the solution. The 
resin was then filtered, and solvent was evaporated to obtain peptide thioester 3g which was 
analyzed by HPLC and MS. 
Initially, the reaction was performed at room temperature using DMF as a solvent in the presence 
of a thiol and without use of any base (entry 1, Table 2.4). This resulted in the release of 10% 
peptide thioester 3g from the resin after treatment for 20 h. To increase the conversion to peptide 
thioester 3g, various bases such as DIEA, DBU and sodium thiolate were investigated (entries 2-4, 
Table 2.4). Addition of a catalytic amount of sodium thiolate (0.5 equiv. with respect to resin) as a 
base significantly increased the yield of peptide thioester 3g released from the resin (85 %; entry 
4, Table 2.4). Since it is difficult to remove DMF from the reaction mixture, a more volatile solvent 
such as ACN was explored, but resulted in very low conversion to a peptide thioester 3g (15 %; 
entry 5, Table 2.4). The final yields in ACN were low due to the poor solubility of sodium thiolate 
in ACN. Temperatures higher than 60 °C resulted in the significant hydrolysis of peptide thioester 
3g into the corresponding acid (entries 7 – 9, Table 2.4). The formation of the hydrolyzed product 
was circumvented by the use of ethyl-3-mercaptopropionate, which gave stable peptide thioester 
3G that is less susceptible to hydrolysis as analyzed by HRMS (Spectra 2.4) and NMR (Spectra 2.5 
– 2.12). All reactions were clean at room temperature irrespective of the nature of thiol used and 
did not show significant amounts of hydrolysis. 
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Table 2.4  Synthesis of peptide thioester Ac-GPMLA-COSR from activated peptide Ac-
GPMLA-Oxd-Rink AM on solid support.a 
 
 
 
 
Entry Base (equiv.) Solvent Temp. (°C) Time (h) 
Conv. (%)b                                            
3g     3G 
1 - DMF RT 20 10 15 
2 DBU (5 equiv.) DMF RT 20 40 c 60 
3 DIEA (20 equiv.) DMF RT 20 60 c 65 
4 PhSNa (0.5 equiv.) DMF RT 20 85 c 99 
5 PhSNa (0.5 equiv.) ACN RT 20 15 c 25 
6 PhSNa (0.5 equiv.) DMF RT 5 30 35 
7 PhSNa (0.5 equiv.) DMF HS, 60 °C 20 10 c 70 c 
8 PhSNa (0.5 equiv.) DMF HS, 60 °C 5 30 c 99 
9 PhSNa (0.5 equiv.) DMF HS, 60 °C 3  50 c 99 
aReaction conditions: Cyclic urethane activated peptide Ac-GPMLA-Oxd, 2g (25 mg, 0.7 
mm/g) on solid support was reacted with thiol (100 µL), and base (0.5-20 equiv.), in DMF (1 
mL). bConversion to peptide thioester Ac-GPMLA-COSR 3g or Ac-GPMLA-COSR 3G was 
calculated from the absorbance at 220 nm using HPLC. cActivated peptide was completely 
released from the resin but hydrolysis product was observed along with the thioester 3g. SR = 
S-(CH2)2-OH or S-(CH2)2-COOC2H5, HS = heated shaker, RT = room temperature, Entries in 
bold: optimized conditions. Thioesterification at high temperature leads to 5 % epimerization. 
Reprinted with permission from reference 1. 
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Spectra 2.4  HRMS Spectra of Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 
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Spectra 2.5  1H NMR for Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 
 
Spectra 2.6  13C NMR for Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 
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Spectra 2.7  1H NMR Spectra for Ac-Gly-Pro-Met-Leu-Ala(D)-COS(CH2)2CO2C2H5 
 
Spectra 2.8  13C NMR Spectra for Ac-Gly-Pro-Met-Leu-Ala(D)-COS(CH2)2CO2C2H5 
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Spectra 2.9  1H / 1H COSY NMR Spectra for Ac-Gly-Pro-Met-Leu-Ala(D)-COS(CH2)2CO2C2H5 
 
Spectra 2.10  1H / 13C HMQC NMR Spectra for Ac-Gly-Pro-Met-Leu-Ala(D)-COS(CH2)2CO2C2H5 
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Spectra 2.11  1H / 13C HMBC NMR Spectra for Ac-Gly-Pro-Met-Leu-Ala(D)-COS(CH2)2CO2C2H5 
Spectra 2.12 1H / 1H ROESY NMR Spectra for Ac-Gly-Pro-Met-Leu-Ala(D)-COS(CH2)2CO2C2H5 
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2.4.6 Evaluation of potential epimerization during thiolysis reaction. 
To investigated potential epimerization during the thioesterification process, we synthesize a 
peptide thioester Ac-GPMLA(L)-COS(CH2)2OH 3g and epimer Ac-GPMLA(D)-COS(CH2)2OH 
3gʹ under optimized reaction conditions. The results showed no detectable levels of epimerization 
as observed by HPLC analysis (Figure 2.3). Next, we investigated epimerization studies on peptide 
thioester Ac-GVALF(L)-COS(CH2)2-COOC2H5 3j with bulky Phe residue at the C-terminus by 
analyzing it with epimer Ac-GVALF(D)-COS(CH2)2-COOC2H5 3jʹ (Spectra 2.13 – 2.15). Less than 
1 % of epimerization was observed as analyzed by HPLC (Spectra 2.14). Although Phe is known 
as an amino acid relatively prone to epimerization, results from these studies indicated that our new 
methodology did not afford substantial epimerization.  
 
Figure 2.3  HPLC traces of (a) purified peptide thioester Ac-GPMLA(L)-COS(CH2)2OH 3g (b) 
purified peptide thioester diastereoisomer Ac-GPMLA(D)-COS(CH2)2OH 3gʹand (c) mixture 
containing both diastereoisomers of peptide thioesters 3g and 3gʹ, demonstrating lack of detectable 
epimerization. SR = S(CH2)2OH. Reprinted with permission from reference 1. 
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Spectra 2.13  HPLC and MS traces of purified peptide thioester Ac-GVALF(L)-COSR 3j 
 
Spectra 2.14  HPLC and MS of purified peptide thioester epimer Ac-GVALF(D)-COSR 3jʹ 
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Spectra 2.15  HPLC trace of mixture containing both diastereoisomers of peptide thioesters Ac-
GVALF(L)-COSR and Ac-GVALF(D)-COSR.  RSH=SH-(CH2)2-COOHC2H5 
2.4.7 Evaluation of different amino acids, protecting groups and resins for the synthesis of 
peptide thioesters. 
To evaluate the effect of different amino acids and protecting groups on the synthesis of peptide 
thioesters, we synthesized a number of peptides with different amino acids and protecting groups 
then evaluated them for the synthesis of peptide thioesters (Table 2.5). The protecting groups were 
subsequently removed from the resulting thioester by a TFA cleavage cocktail in solution. It was 
noted that the formation of peptide thioesters is independent of nature of amino acid residues 
preceding serine. For example, peptides with a bulky amino acid residue next to serine such as 
Glu(tBu), Phe, and Ser(tBu) and peptide with β-branched residues such as Val and Thr(tBu) 
generated the protected peptide thioesters in a clean manner and with high yields (entries 2-6, Table 
2.5). These studies concluded that the cyclic urethane activated peptide will be a versatile precursor 
for the synthesis of peptidyl thioesters. 
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Next, the peptide backbone activation was investigated with threonine, whose side chain 
functionality exhibits strong similarity with serine. As expected, threonine underwent smooth 
cyclization under the optimized reaction conditions and generated activated peptide Ac-GPMLA- 
MeOxd 2n (entry 7, Table 2.5). In a similar manner, cysteine generated thiazolidinone activated 
peptide Ac-GPMLA-Thz 2o under the reaction conditions (entry 8, Table 4). The activated peptides 
2n and 2o generated peptide thioester 3G in high yields upon thiolysis.  
We also noted cyclic urethane method is independent of the nature of resin that was used and 
worked equally well with Tentagel, Wang and Chemmatrix resins. 
Table 2.5  Fmoc SPPS of peptide thioesters via activated serine.a 
 
 
 
 
 
Entry Substrate Peptide Conv. (%) b 
1 2h Ac-AVGPPGVA-Oxd 95 
2 2i Ac-R(Pbf)AFK(Boc)Y(tBu)GLE (tBu)-Oxd 95 
3 2j Ac-GVALF-Oxd 95 
4 2k Ac-Y(tBu)FD(tBu)IR(Pbf)AV-Oxd 90 
5 2l Ac-S(tBu)GIS(tBu)GPLS(tBu)-Oxd 95 
6 2m Ac-RFAT-(tBu)Oxd 90 
7 2n Ac-GPMLA-MeOxd 95 
8 2o Ac-GPMLA-Thz 90 
    
aReaction conditions: Activated peptide, 2 (25 mg, 0.7 mm/g) on solid support was reacted with 
ethyl-3-mercaptopropionate (100 µL), and catalytic amount of sodium thiolate (0.5 equiv.), in 
DMF (1 mL). bConversion to peptide thioester 3 was calculated from the absorbance at 220 nm 
using HPLC. SR = S-(CH2)2-COOC2H5. Reprinted with permission from reference 1. 
2.4.8 Synthesis of multiserine containing bioactive peptide thioester. 
Next, we test our optimized method to synthesize a multiserine containing peptide to demonstrate 
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selectivity of the serine residue for the formation of the cyclic urethane moiety and subsequent 
thioester synthesis. The method was successfully applied for the synthesis of a multiserine 
containing bioactive peptide thioester Ac-SGISGPLS-COS(CH2)2COOC2H5 3L, a fragment of 
antimicrobial bovine beta-defensine 13,26 from cyclic urethane activated peptide Ac-
S(tBu)GIS(tBu)GPLS(tBu)-Oxd 2l (Figure 2.4).  
 
Figure 2.4  Cyclic urethane technique for the synthesis of the fragment of antimicrobial bovine 
beta-defensin 13 bioactive peptide thioester 3Land 19 amino acid long fragment of rabies virus 
glycoprotein (Rvg) peptide thioester 3P. (a) HPLC trace of pure bioactive peptide thioester 
3L; inset shows MS of peptide thioester 3L. (b) HPLC trace of pure bioactive peptide thioester 3P; 
inset shows MS of peptide thioester 3P.SR= S-(CH2)2-COOC2H5. Reprinted with permission from 
reference 1.  
Since the main role of peptide thioesters is to synthesize complex proteins and bioconjugates, it is 
important that the cyclic urethane moiety is capable of making long peptide thioesters with diverse 
functional groups. To test the compatibility of the cyclic urethane technique, nineteen amino acid 
long peptide thioester Ac-RMITYGNSARKGRSNTFID-COS(CH2)2-COOC2H5 3P, a fragment of 
rabies virus glycoprotein (Rvg),19,27 was successfully synthesized from corresponding cyclic 
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urethane moiety 2p with a yield of 31% (b, Figure. 2.4). These results (Fig. 2.4) and Table 2.5 
demonstrated the versatility of the cyclic urethane technique in the synthesis of peptide thioesters. 
2.4.9 Utilization of Peptide Thioester for Native Chemical Ligation  
To demonstrate the applicability of the optimized technique for NCL, we utilized peptide thioesters 
Ac-GPMLA-COS-(CH2)2-COOC2H5 3G and Ac-AVGPPGVA-COS-(CH2)2-COOC2H5 3h 
generated by cyclic urethane technique in Native Chemical Ligation (NCL) with N-terminal 
cysteine containing peptide Ac-SAFRC-NH2 (Figures 2.4 and 2.5). In addition, cyclic urethane 
technique-derived 14 amino acid long peptide thioester Ac-GNSARKGRSNTFID-COSR 3Q (39% 
yield) was ligated with N-terminal cysteine-containing peptide CPTGPRPNEPMWITYNH2 to 
generate a 29 amino acid long peptide fragment of rabies virus glycoprotein (Rvg), an effective 
carrier for cargo delivery into cells and for crossing the blood–brain barrier (Figure. 2.6).27 
We also noted that relatively dilute conditions were used for the peptide reactants (1.2 mM) as well 
as low concentrations of the 4-mercaptophenylacetic acid catalyst (25 mM). The ligation was 
completed after 24 h at 37 °C, demonstrating the utility of cyclic urethane technique in the synthesis 
of peptide thioesters for the formation of large peptides using NCL.  
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Figure 2.5  Native chemical ligation of peptide thioester Ac-GPMLA-COSR 3G with N-terminal 
cysteine peptide CRFAS-NH2. HPLC/MS traces of peptide thioester 3G and ligated product. 
Ligation conditions: 1.3 mM thioester, 2 mM CRFAS in ligation buffer (0.2 M sodium phosphate 
and 6 M guanidine HCl), 20 mM MPAA, 17 mM TCEP. HCl and pH of the solution is 7.1. SR = 
S-(CH2)2-COOC2H5. Reprinted with permission from reference 1.  
 
Figure 2.6  Native chemical ligation of peptide thioester Ac-AVGPPGVACOSR 3h with N-
terminal cysteine peptide CRFAS-NH2. HPLC/MS traces of peptide thioester 3h and ligated 
product. SR = S-(CH2)2-COOC2H5. 
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Figure 2.7  Ligation of peptide thioester Ac-GNSARKGRSNTFID-COSR 3Q with N-terminal 
cysteine peptide CPTGPRPNEPMWITY-NH2. MS of the ligated product. SR = S-(CH2)2-
COOC2H5. 
2.5 Conclusion 
We have developed a novel cyclic urethane activation technique for the synthesis of peptide 
thioesters directly from solid support. The cyclic urethane technique activates the peptide 
backbone, which undergoes nucleophilic displacement by a thiol to release a corresponding 
thioester into the solution. The significant advantage of this technique is that unnatural handles or 
linkers are not required, and synthesis of peptides is carried out by Fmoc-SPPS without a need for 
any special reaction conditions and can be fully automated, thus constituting a major advance in 
the field. It is noteworthy that only those peptides that undergo complete activation are displaced 
by the thiol into the solution thus delivering very pure thioesters in the solution. Moreover, 
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activation of serine to form the cyclic urethane moiety and subsequent thiolysis is compatible with 
both bulky amino acids including β-branched residues such as Phe/Val next to serine and is resistant 
to epimerization. The results suggest that the cyclic urethane activation technique will be utilized 
in organic synthesis, including peptide and protein chemistry. Moreover, the cyclic urethane ring 
is stable and can be stored in the desiccator for long periods of time without any disintegration. The 
applicability of the strategy was demonstrated by the synthesis of a long peptide thioester, which 
was utilized for the synthesis of a 29 amino acid long peptide derived from rabies virus glycoprotein 
(Rvg) using NCL. The synthesis of C-terminally activated cyclic urethane peptides and peptide 
thioester for NCL is compatible for the synthesis of wide variety of complex post-translationally 
modified peptides. This strategy is also a powerful tool that can be used for site specific 
modification of peptide / protein with N-terminal cysteine residues as well as the synthesis of other 
complex biomolecules.  
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2.6 Methods and Materials 
General:  All commercial materials (Aldrich, Fluka, Nova) were used without further purification. 
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2, 
and DMF were obtained from a dry solvent system (passed through column of alumina) and used 
without further drying. All reactions were performed under air in round bottom flask. Yields refer 
to chromatographically pure compounds; % yield were obtained by comparison of HPLC peak 
areas of products and starting material. HPLC was used to monitor reaction progress. 
Materials: Fmoc-amino acids were obtained from Nova Biochem is under (EMD Millipore 
Corporation) (Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin 
was obtained from ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O-
(1Hbenzotriazol-1-yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus 
(Louisville, Kentucky). N, N′-Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, 
under (EMD Millipore Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine 
(DMAP): Merck KGaA (Darmstadt, Germany). N,NDimethylformamide (DMF): Macron Fine 
Chemicals (Center Valley, Pennsylvania). 
Dichloromethane (DCM), acetonitrile, N,N- Diisopropylethylamine (DIEA), N,N'-
diisopropylcarbodiimide (DIC), Triethylsilane (TES), were purchased from (EMD Millipore 
Corporation) (Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, 
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford 
RoadRadnor, PA. Diethyl Ether, 4-mercaptophenylacetic acid (MPAA), sodium thiophenolate 
(NaSPh), and Tris(2-carboxyethyl) phosphine hydrochloride TCEP.HCl : Sigma Aldrich (St. Louis, 
Missouri). Water was purified using a Millipore Milli-Q water purification system. 
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NMR: (NMR analysis done by Ryan Cohen at Merck, Rahway NJ) 
Proton NMR spectra were recorded on a 600 MHz spectrometer and carbon NMR spectra on a 151 
MHz, spectrometer at ambient temperature. All NMR chemical shifts (δ) are referenced in ppm 
relative to residual solvent or internal tetramethylsilane. 1H NMR chemical shifts referenced to 
residual DMSO-d5 at 2.50 ppm, and 13C NMR chemical shifts referenced to DMSO-d6 at 39.52 
ppm. Carbon NMR spectra are proton decoupled. NMR spectral data are reported as chemical shift 
(multiplicity, coupling constants (J), integration). Multiplicity is reported as follows: singlet (s), 
broad singlet (bs), doublet (d), doublet of doubles (dd), doublet of triplet (td), triplet (t) and 
multiplet (m). Coupling constant (J) in Hertz (Hz). 
HPLC 
Semi-Preparative HPLC: Preparative HPLC chromatography (HPLC) was performed on 
Beckman Coulter equipped with System Gold 168 detector and 125P solvent module HPLC with 
C-18 reversed-phase column. All separations involved a mobile phase of 0.1% FA (v/v) in water 
(solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using a 
linear gradient of 0–80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a 
flow rate of 3.0 mL min-1. The eluent was monitored by absorbance at 220 nm unless otherwise 
noted. 
Analytical HPLC:  Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100 
series HPLC equipped with a 4.6 mm C-18 reversed-phase column. All separations involved mobile 
phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide 
compositions were evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in 
acetonitrile versus 0.1% FA in water. Analytical HPLC method using a linear gradient of 0–80% 
0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate 
of 1.0 mL min-1. The eluent was monitored by absorbance at 220 nm unless otherwise noted. 
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LCMS:  Mass spectrometry was performed using ultra high performance liquid chromatography-
mass spectrometry using the Agilent 1100 Series LCMSD VL MS Spectrometer. 
Fmoc Solid-Phase Peptide Synthesis:28  Peptides were synthesized manually on a 0.25 mm scale 
using Rink amide resin. Fmoc–group was deprotected using 20% piperidine–DMF for 20 min to 
obtain a deprotected peptide-resin. Fmoc-protected amino acids (1.25 mm) were sequentially 
coupled on the resin using a HBTU (1.25 mm) and DIEA (1.25 mm) for 2 h at room temperature. 
Peptides were synthesized using standard protocols.28 The peptide was cleaved from the resin using 
a cocktail of 95:2.5:2.5, trifluoroacetic acid: triisopropyl silane:water for 2 h. The resin was 
removed by filtration and the resulting solution was concentrated. The oily residue was triturated 
with diethyl ether to obtain a white suspension. The resulting solid was purified by HPLC. 
General procedure for the activation of serine to cyclic urethane moiety on solid support: 
 
Scheme 2.3  Activation of serine to cyclic urethane moiety on solid support 
To a peptide on the solid support (25-100 mg, 0.69 mm/g) was added a solution of DSC (10 equiv.), 
DIEA (10 equiv.) and catalytic amount of DMAP in dimethylformamide (DMF). The resin was left 
on the shaker for 17 h. The solution was drained and resin was washed with DMF followed by 
cleavage using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 h. The 
resin was removed by filtration and the resulting solution was concentrated. The oily residue was 
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triturated with diethyl ether to obtain a white suspension. The resulting solid was purified by HPLC 
and analyzed by MS and NMR. 
.  
 
Figure 2.8  HPLC Trace of l. 
HPLC Trace: Retention time = 15.37, Purity: >95% (HPLC analysis at 220 nm) 
HRMS: m/z 384.155, (calcd [M+H]+ = 384.148) 
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Spectra 2.16  1H NMR of l. 
 
Spectra 2.17  13C NMR of l. 
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Figure 2.9  HPLC Trace of ll. 
HPLC Trace: Retention time = 15.37, Purity: >95% (HPLC analysis at 220 nm) 
HRMS: m/z 384.155, (calcd [M+H]+ = 384.148) 
NMR 
1H NMR chemical shifts referenced to residual DMSO-d6 at 2.50 ppm, and 13C NMR chemical 
shifts referenced to DMSO-d6 at 39.52 ppm. 
1H NMR (600 MHz, DMSO-d6) δ 7.90 (d, J = 7.5 Hz, 2H), 7.75 (s, 1H), 7.72 (d, J = 7.4 Hz, 
2H),7.64 (t, J = 6.0 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.39 (s, 1H), 7.33 (t, J = 7.4 Hz, 2H), 4.73 
(dd, J = 9.1, 3.1 Hz, 1H), 4.60 (t, J = 9.0 Hz, 1H), 4.36 – 4.15 (m, 6H). 
 
13C NMR (151 MHz, DMSO-d6) δ 169.9, 169.1, 156.4, 153.5, 143.8, 140.7, 127.6, 127.1, 125.2, 
120.1, 66.8, 65.8, 55.4, 46.6, 44.1. 
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Figure 2.10  Comparison of NMR chemical shifts for serine to cyclic urethane moiety vs six 
membered ring. 
 
Spectra 2.18  1H NMR of ll. 
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Spectra 2.19  13C NMR of ll. 
General procedure for the synthesis of peptide thioesters from solid support 
 
 To an activated peptide as cyclic urethane moiety on the solid support (25 mg – 0.7 mm/g), thiol 
(100 μL), catalytic amount of sodium thiolate (0.5 equiv.) and 1 mL of DMF was added and resin 
was left on shaker at room temperature for 20 h. The resin was filtered which is followed by the 
removal of solvent under high vacuum. The resulting peptide thioester was analyzed by MS and 
HPLC. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 
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0-80 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 
nm. 
NMR and MS of Peptide Thioesters 
NMR spectra were recorded on a Bruker 600 MHz AVANCE III HD spectrometer with a triple 
resonance TXI probe at ambient temperature. Each sample was fully dissolved in 150 μL DMSO-
d6 and transferred to a 3 mm NMR tube. Data are reported as follows: 1H NMR chemical shifts in 
parts per million (δ, ppm) referenced to residual DMSO-d6 at 2.50 ppm and 13C NMR chemical 
shifts in parts per million (δ, ppm) referenced to DMSO-d6 at 39.52 ppm. Multiplicity abbreviations 
are s = singlet, d = doublet, t = triplet, q = quartet, om = overlapped multiplet, and proton-proton 
coupling constants (J) were measured in Hz. HRMS data were recorded on an Agilent 6520 Q-ToF 
mass spectrometer using positive polarity electrospray ionization (+ESI). IUPAC nomenclature 
generated by ACD Labs, version 12.5.  
N-acetylglycyl-N-[(5S,8S, 11S)-11-methyl-8-(2-methylpropyl)-6,9,12,16-tetraoxo-17-oxa- 2,13-
dithia-7,10-diazanonadecan-5-yl]-L-prolinamide: 1H NMR (600 MHz, DMSO-d6) δ 8.40 (d, J = 
7.5 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 8.00 (t, J = 6.0 Hz, 
1H), 7.75 (d, J = 8.2 Hz, 1H), 4.42-4.24 (om, 4H), 4.06 
(q, J = 7.0 Hz, 2H), 3.94-3.82 (om, 2H), 3.58-3.45 (om, 
2H), 2.96 (t, J = 6.9 Hz, 2H), 2.54 (t, J = 6.9 Hz, 2H), 
2.48-2.38 (om, 2H), 2.06-2.03 (om, 1H), 2.02 (s, 3H), 1.96-1.87 (om, 4H), 1.86 (s, 3H), 1.83-1.75 
(om, 1H), 1.59-1.41 (om, 3H), 1.25 (d, J = 7.2 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H), 0.88 (d, J = 6.8 Hz, 
3H), 0.84 (d, J = 6.4 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ 201.4, 172.0, 171.8, 171.1, 170.8, 
169.5, 167.5, 60.2, 59.7, 54.8, 52.2, 51.0, 46.1, 41.4, 40.6, 33.7, 31.5, 29.6, 29.1, 24.3, 24.2, 23.2, 
22.9, 22.4, 21.6, 17.2, 14.6, 14.1. HRMS (+ESI) calc. for C28H48N5O8S2+: 646.2939, found 646.2946 
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N-acetylglycyl-N-[(5S,8S,11R)-11-methyl-8-(2-methylpropyl)-6,9,12,16-tetraoxo-17-oxa- 
2,13-dithia-7,10-diazanonadecan-5-yl]-L-prolinamide: 1H NMR (600 MHz, DMSO-d6) δ 8.50 
(d, J = 7.1 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.00 (t, J 
= 5.5 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 4.39-4.24 (om, 
4H), 4.06 (q, J = 7.2 Hz, 2H), 3.91 (dd, J = 16.9, 5.5 
Hz, 1H), 3.84 (dd, J = 17.0, 5.3 Hz, 1H), 3.57-3.43 
(om, 2H), 2.97 (t, J = 6.9 Hz, 2H), 2.54 (t, J = 7.0 Hz, 
2H), 2.48-2.37 (om, 2H), 2.03 (s, 3H), 1.96-1.87 (om, 
3H), 1.85 (s, 3H), 1.82-1.74 (om, 2H), 1.67-1.60 (m, 1H), 1.57- 1.43 (om, 3H), 1.26 (d, J = 7.3 Hz, 
3H), 1.18 (t, J = 7.2 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.5 Hz, 3H). 13C NMR (151 
MHz, DMSO-d6) δ 201.6, 172.0, 171.7, 171.1, 170.8, 169.4, 167.4, 60.2, 59.6, 54.8, 51.9, 50.7, 
46.0, 41.4, 40.4, 33.7, 31.6, 29.6, 29.1, 24.3, 24.1, 23.2, 23.1, 22.4, 21.5, 17.2, 14.7, 14.1. HRMS 
(+ESI) calc. for C28H48N5O8S2 +: 646.2939, found 646.2932. 
General procedure for the native chemical ligation for synthesis of large peptides 
 
900 μL of ligation buffer pH 7.1 (0.2 M sodium phosphate buffer and 6 M guanidine hydrochloride) 
was added to 1.0 mg of the peptide thioester 3G/3h (final concentration 1.3 mM) and 1.3 mg of 
peptide CRAFS (final concentration 2 mM) under argon. The mixture was treated with MPAA (3.8 
mg, 20 mM) and TCEP.HCl (5.5 mg, 17 mM) and pH of solution was adjusted to 7.0 by using 2N 
NaOH solution. The ligation was carried out at 37°C and monitored by RP HPLC. After completion 
of reaction, TCEP (30 mM in water) was added into the reaction mixture and it was left for stirring 
at room temperature for 1 h followed by purification of ligated peptide using RP-HPLC.  
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 Chapter 3  
Development of Secondary Amine Selective Petasis (SASP) 
Bioconjugation 
3.1 Abstract  
Selective modification of proteins enables synthesis of antibody-drug conjugates, cellular drug 
delivery and construction of new materials. Many groups have developed methods for selective N-
terminal modification without affecting the side chain of lysine by judicious pH control. This is 
due to lower basicity of the N-terminus relative to lysine side chains. But none of the methods are 
capable of selective modification of secondary amines or N-terminal proline, which has similar 
basicity as lysine. This chapter discusses the development of a secondary amine selective Petasis 
(SASP) reaction for selective bioconjugation at N-terminal proline. We exploited the ability of 
secondary amines to form highly electrophilic iminium ions with aldehydes, which rapidly reacted 
with nucleophilic organoboronates, resulting in robust labeling of N-terminal proline under 
biocompatible conditions. This is the first time the Petasis reaction has been utilized for selective 
modification of secondary amines on completely unprotected peptides and proteins under 
physiological conditions. Peptide screening results showed that the reaction is highly selective for 
N-terminal proline. There are no other chemical methods reported in literature that are selective for 
N-terminal proline in both peptides and proteins. This is a multicomponent reaction leading to the 
synthesis of doubly functionalized bioconjugates in one step that can be difficult to achieve using 
other methods. The key advantage of the SASP reaction includes its high chemoselective and 
stereoselective (>99% de) nature, and it affords dual labeled proteins in one pot. The broad utility 
of this bioconjugation is highlighted for a variety of peptides and proteins, including aldolase and 
creatine kinase. 
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Figure 3.1  Graphical Abstract of Secondary amine selective Petasis (SASP) bioconjugation. 
Figure adopted with permission from: Sim, Y. E.; Nwajiobi, O.; Mahesh, S.; Cohen, R. D.; 
Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61. 
3.2 Chapter Objective 
This chapter describes the development of a secondary amine selective Petasis (SASP) reaction for 
selective modification of N-terminal proline containing peptides and proteins. The design of the 
reaction is derived from the well-known Petasis reaction. Petasis reaction is a three-component 
reaction of a amine, an aldehyde and organoboron reagent. Since this is the first time classical 
Petasis reaction has been used for protein modification the reactivity and selectivity of the reaction 
were evaluated first on peptides and the optimal conditions were determined. The chemoselectivity 
of the reaction to modifies only N-terminal proline was verified by competition reactions using 
mixtures of peptides. Stability of the Petasis product was evaluated to a variety of conditions. The 
stereoselective nature of SASP reaction was validated and confirmed by NMR results. Mechanistic 
studies were performed determine the role of aldehyde and boronic acid in the reaction. The dual 
labelling capability of the method was assessed with diverse functional groups. The secondary 
amine selective nature of the reaction was demonstrated by modification biologically active 
peptides and protein with proline at the N-terminal. 
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3.3 Introduction 
The site-selective synthetic modification of proteins enables the construction of biomolecular 
hybrids for a multitude of bioanalytical,2 therapeutic, chemical biology3 and bioengineering 
applications.4-6 The synthesis of these constructs requires chemoselective and regioselective 
bioconjugation reactions that proceed under ambient, aqueous conditions at a kinetically favorable 
rate. Common methods for selective protein modification include alkylation of introduced cysteine 
residues,7 targeting artificial amino acids with distinct reactivity,8–10 native chemical ligation,11,12 
and enzymatic labeling techniques.13,14 There have been several reported methods for specific 
labeling of particular amino acids at the N-terminus, such as cysteine,11 tryptophan,15 serine,16,17 
and threonine.16,17 Some groups developed methods for targeting the N-terminus of proteins, while 
avoiding lysine modification by controlling the reaction pH.18–20 Our group utilized a 
transamination approach and aldol chemistry for selective modification of protein N-termini.21 
Recently, Francis and co-workers developed a robust method for the N-terminal modification of 
proteins.22 But none of these methods are capable of labeling secondary amines or N-terminal 
proline in a selective manner in both peptides and proteins. Here, we report a multicomponent 
secondary amine selective Petasis (SASP) bioconjugation method for selective labeling of N-
terminal proline of peptides and proteins. Previously, a method for modification at N-terminal 
proline was attempted through oxidative coupling with an amino phenol;23 however, it leads to the 
modification of any amino acid at the N-terminus of peptides. The chemoselectivity was not 
observed for proline over other amino acids in peptides. The oxidative approach also leads to the 
modification of cysteine; thus, cysteine protection was required for selective labeling.23 To the best 
of our knowledge, there has been no chemical method reported for selective labeling of secondary 
amines, such as proline, in peptides and proteins under physiological conditions. A major chemical 
challenge that accompanies the development of a reaction that selectively modifies proline (pKa = 
10.5) is the presence of competing, more reactive primary amino acids (pKa = 9.5), and the equally 
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reactive side chain of lysine (pKa = 10.6).23 The secondary amine selective Petasis (SASP) reaction 
accomplishes this goal by exploiting the ability of secondary amines to form more electrophilic 
reactive iminium ions (1A, Figure 3.2) towards nucleophilic organoboronates as compared to 
imines (1B, Figure 3.2) obtained from primary amines.24,25 
This makes the secondary amine selective Petasis (SASP) bioconjugation quite different from other 
methodologies attempted in literature. Peptide substrates were first screened to identify the 
site of modification. The results showed high selectivity for N-terminal proline over any other 
amino acids. We did not observe modification of any other amino acids. The reaction was then 
applied to protein substrates, showing similarly high conversions when an N-terminal proline 
residue was present. This multicomponent reaction dually labeled the peptides and proteins in one 
pot under physiological conditions with various cargoes. Moreover, the SASP reaction generated a 
chiral center at the site of conjugation with high stereoselectivity. This was most likely due to the 
tendency of proline to induce asymmetric induction through the iminium ion mechanism.26 Unique 
selectivity, operational simplicity, no catalyst requirement, fast reaction kinetics, ability to generate 
a stable C–C bond, and physiological conditions are the major strengths of the SASP 
bioconjugation. 
3.4 Results and Discussion  
3.4.1 Design of Petasis reaction for selective modification of secondary amines 
The design of one-step, site selective, and dual labelling of secondary amines/proline in completely 
unprotected peptides and proteins is derived from the well-known Petasis reaction, which forms 
stable C–N and C–C bonds at the site of conjugation between amine, aldehyde and organoboron 
reagent. Key features that caught our attention for choosing the Petasis reaction for developing a 
secondary amine selective bioconjugation reaction are (i) the moderately high reactivity of the 
Petasis reaction for secondary amines in contrast to primary amines and ammonia; (ii) the exclusive 
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preference of boronic acid to attack the carbon–nitrogen double bond, over any carbon–oxygen 
double bonds; (iii) the compatibility of Petasis reaction with water;27 (iv) stability of organoboron 
reagents towards air and moisture, (v) tolerance to a broad range of reactive functional groups; and 
(vi) the multicomponent nature of the Petasis reaction to provide a method for dual labeling of 
proteins in one-pot. In our design of the SASP reaction we were guided by a thorough kinetic study 
of the classical Petasis reaction indicating that formation of an imine/iminium ion intermediate is 
partially rate limiting.28 Taking note of the rapid rates at which amines condense with aldehydes 
and ketones, we anticipated that the rate of the iminium ion formation would be faster than the 
imine formation because of the high nucleophilicity of secondary amines (N = 17) as compared to 
primary amines (N = 12) in water25 (Figure. 3.2). Moreover, iminium ions obtained from secondary 
amines are more electrophilic as compared to imines toward organoboronates at physiological pH 
7.3. This was most likely due to the low basicity of imines (pKa ~ 9), which remained unprotonated 
under physiological conditions. These points suggested that the SASP reaction could be utilized for 
chemo- and site selective labeling of N-terminal proline under physiological conditions. Thus, this 
method was utilized for selective functionalization of biological molecules containing N-terminal 
proline that are native or readily introduced by standard site directed mutagenesis.29 
 
Figure 3.2  Proposed high reactivity and selectivity towards secondary amines compared to primary 
amines. Figure adopted with permission from: Sim, Y. E.; Nwajiobi, O.; Mahesh, S.; Cohen, R. D.; 
Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61. 
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3.4.2 Evaluating the reactivity and selectivity of the SASP reaction on peptides 
Initial experiments were designed to identify the optimal reaction conditions for labeling biological 
molecules containing N-terminal proline. The high chemoselectivity of the SASP reaction for N-
terminal proline was determined by carrying out reactions with tripeptides XAF, where X was 
substituted with 19 different canonical amino acids (pKa = 9.5) including amino acids with reactive 
side chains such as Lys, Thr, Ser, Asn, Gln, Glu, Asp, Tyr, Trp, Met and Cys (Figure. 3.3). These 
peptides were synthesized on solid support using standard Fmoc synthesis, cleaved from the resin, 
and purified by HPLC. After purification and lyophilization, peptides were exposed to 
salicylaldehyde SAL 2a and phenylboronic acid PBA 3a. The reactions were carried out in 25 mM 
phosphate buffer (pH 7.3) : DMF (4 : 1) at room temperature, and reaction mixtures were analyzed 
by LCMS (Figure. 3.3). DMF was used as a cosolvent due to the low solubility of PBA 3a in 
aqueous buffer. The results showed 70 conversion to Petasis product 4a with peptide PAF 1a 
containing proline at the N-terminus (Figure. 3.3). The formation of the Petasis product with 
peptides XAF containing primary amino acids at the N-terminus was not detected, thereby showing 
that SASP exhibited high selectivity for secondary amines. A second observation of this screen was 
the fact that lysine and cysteine side chains were not modified under the reaction conditions. 
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Figure 3.3  Chemoselectivity of SASP reaction for N-terminal proline. The reaction showed high 
selectivity for N-terminal proline as analyzed by LC/MS for a panel of XAF peptides, where X 
represents a variable amino acid. Reaction conditions: 2 mg XAF (12–17 mM, SAL 2a (3 equiv., 
36–51 mM), PBA 3a (4 equiv., 48–68 mM) in buffer (pH 7.3) : DMF (4 : 1) at room temperature 
for 4–24 h. Figure adopted with permission from: Sim, Y. E.; Nwajiobi, O.; Mahesh, S.; Cohen, R. 
D.; Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61. 
3.4.3 Verification that SASP modifies only N-terminal proline under physiological 
conditions. 
The chemoselectivity of SASP reaction towards N-terminal proline was further verified by 
competition reactions using a mixture of two peptides, PAF 1a and XAF (X = Ala, Glu, Arg, Val, 
Asn, Asp, Ser, Trp, Tyr, Leu, Lys, and Met), in one-pot (Figure. 3.4). Different peptides were mixed 
together and exposed to SAL 2a and PBA 3a in 25mMphosphate buffer (pH 7.3): DMF    (4 : 1) 
solution. Among all combinations, the Petasis product 4a was observed from peptide PAF 1a only, 
while the other peptides XAF did not lead to any products under any tested conditions (Figure. 3.4). 
82 
 
 
 
Figure 3.4  Verification of chemoselectivity of the SASP reaction for secondary amines. Reactions 
with a mixture of two peptides PAF 1a and XAF 1 (X = Ala, Glu, Arg, Val, Asn, Asp, Ser, Trp, 
Tyr, Leu, Lys, and Met) in one pot. The reaction showed Petasis product 4a corresponding to 
peptide PAF only. Reaction conditions: PAF 1a (2 mg, 15 mM), XAF 1 (2 mg, 12-17 mM), SAL 
2a (3 equiv., 36 mM-51 mM) and PBA 3a (4 equiv., 48 mM-68 mM) in 0.4 mL of 25 mM phosphate 
buffer (pH 7.3) : DMF (4 : 1) at RT. Figure adopted with permission from: Sim, Y. E.; Nwajiobi, 
O.; Mahesh, S.; Cohen, R. D.; Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61. 
Next, peptide PAF 1a and SAL 2a were exposed to more water-soluble p-methoxyphenyl boronic 
acid PMB 3b and reaction was carried out under physiological conditions in 25mMphosphate 
buffer (pH 7.3) : DMSO (4 : 1). The results showed progressively greater reactivity as 90% 
conversion to Petasis product 4b was achieved within 2 hours as determined by LC-MS. The 
product 4b of Petasis reaction between peptide PAF 1a, SAL 2a and PMB 3b was synthesized on 
larger scale and characterized using two-dimensional NMR and high resolution mass spectrometry 
HRMS (Spectra. 3.1 – 3.7, Figure. 3.5, Table 3.1 and Table 3.2). The greater reactivity of 3b is 
most likely due to the electron-donating group (EDG) at the para position that significantly 
increases nucleophilicity of the phenyl carbanion.29 
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Spectra 3. 1  1HNMR of Petasis product 4b  
 
Spectra 3. 2  13C NMR of Petasis product 4b  
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Spectra 3. 3  1H/1H COSY NMR of Petasis product 4b  
 
Spectra 3. 4  1H/13C HSQC NMR of Petasis product 4b  
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Spectra 3. 5  1H/13C HMBC NMR of Petasis product 4b  
 
Spectra 3. 6  1H/13C TOCSY NMR of Petasis product 4b 
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Spectra 3. 7  1H/1H ROESY NMR of Petasis product 4b  
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Figure 3.5  Structure of Petasis product from reaction FAP-NH2 + 4-methoxyphenylboronic acid 
+ Salicylaldehyde 
1H NMR data for 4b 
Atom 
No. 
Chemical 
Shiftb 
(ppm) 
Multiplicityc Coupling 
Constant 
(Hz) 
Integration 
1’ 7.08 s N/A 1 
1’’ 7.48 s N/A 1 
4 3.14 m N/A 1 
5’ 1.65-1.72 m N/A 1 
5’’ 1.98 m N/A 1 
6 1.60-1.74 m N/A 2 
7’ 2.44 m N/A 1 
7’’ 2.91 m N/A 1 
9 1.13 d 6.8 3 
10 4.05 p 7.0 1 
12 8.15 d 7.7 1 
14 4.49-4.55 m N/A 1 
16 8.06 d 8.2 1 
18, 22 7.27-7.29 m N/A 2 
19, 21 7.24-7.27 m N/A 2 
20 7.19 t 6.9 1 
24’ 2.82 dd 13.8, 9.6 1 
24’’ 3.02 dd 13.8, 4.8 1 
25 6.03 br s N/A 1 
26 6.66 t 7.7 1 
27 6.79 d 7.7 1 
30 7.02 d 7.4 1 
31 9.98 s N/A 1 
32 5.10 s N/A 1 
34, 38 6.87 d 8.2 2 
35, 37 7.35 d 8.2 2 
40 3.71 s N/A 3 
a: Recorded at 600 MHz in DMSO-d6 on a Varian spectrometer 
b: Chemical shifts referenced to TMS at 0.00 ppm 
c: s=singlet, d=doublet, t=triplet, p=pentet, dd=doublet of doublets, br=broad, m=multiplet 
Table 3. 1  1H NMR data for 4b Chemical Shift referenced to TMS.  FAP-NH2 + 4-
methoxyphenylboronic acid + Salicylaldehyde 
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13C NMR data for 4b 
Atom 
No. 
Chemical 
Shiftb 
(ppm) 
2 173.1 
4 63.4 
5 30.2 
6 23.9 
7 53.0 
9 19.2 
10 47.2 
11 171.8 
14 53.9 
15 172.8 
18, 22 129.1 
19, 21 128.0 
20 126.2 
23 137.8 
24 37.5 
25 118.3 
26 127.2 
27 115.1 
28 154.5 
29 128.1 
30 129.0 
32 64.2 
33 157.9 
34, 38 113.6 
35, 37 128.7 
36 134.8 
40 54.9 
a: Recorded at 151 MHz in DMSO-d6 on a Varian spectrometer 
b: Chemical shifts referenced to DMSO-d6 at 39.45 ppm 
Table 3. 2  13C NMR data for 4b Chemical Shift in DMSO-d6. FAP-NH2 + 
4-methoxyphenylboronic acid + Salicylaldehyde 
Further the high selectivity of the SASP reaction for proline in the presence of highly reactive PMB 
3b was verified by carrying out the reaction with a mixture of two peptides PAF 1a and XAF 
(where, X = Glu, Lys, Thr, Trp, Tyr, Leu, and His) and SAL 2a in one pot under physiological 
conditions (Table 3.3). Again, the Petasis product 4b was observed from peptide PAF 1a only. As 
further validation of the reaction site specificity, no modification of lysine and cysteine was 
observed with peptides, PFKAFV and PFCAF, containing both N-terminal proline (pKa 10.5) and 
the reactive side chain of lysine (pKa =10.6) and cysteine (Figure. 3.6 and Figure. 3.7), respectively. 
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Table 3. 3  Chemoselectivity of the SASP reaction for secondary amines with reactive PMB 2b 
under physiological conditions. Reactions with a mixture of two peptides PAF 1a and XAF 1 (X = 
Ala, Glu, Arg, Val, Asn, Asp, Ser, Trp, Tyr, Leu, Lys, and Met), in one pot. The reaction showed 
Petasis product 4b corresponding to peptide PAF only. Reaction conditions: PAF 1a (2 mg, 15 
mM), XAF 1 (2 mg, 12-17 mM), SAL 2a (3 equiv., 36 mM-51 mM) and PMB 3b (4 equiv., 48 
mM-68 mM) in 0.4 mL of 25 mM phosphate buffer (pH 7.3) : DMSO (4 : 1) was stirred at RT for 
4 h. 
 
Figure 3.6  Synthesis and LCMS of Petasis product and compatibility of SASP with free cysteines 
To a peptide PACAF (2 mg, 6.87 mM) in 0.5 mL solution of 25 mM phosphate buffer (pH 7.3): 
DMF (4:1) was added SAL 2a (3 equiv., 20.4 mM), PBA 3a (4 equiv., 27.5 mM). The solution was 
stirred at room temperature for 4 h. The solution was stirred at room temperature for 4 h. The 
reactions were analyzed by LC/MS. LC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) 
acetonitrile (solvent B); gradient 0-60 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 
mL/min, detection wavelength 220 nm. 
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Figure 3.7  Synthesis and LCMS of Petasis product and compatibility of SASP with free lysines 
To a peptide PFKAFV (2 mg, 5.6 mM) in 0.5 mL solution of 25 mM phosphate buffer (pH 7.3): 
DMSO (4:1) was added SAL 2a (3 equiv., 16.8 mM), PMB 3b (4 equiv., 22.4 mM). The solution 
was stirred at room temperature for 4 h. The reactions were analyzed by LC/MS. LC: 0.1% FA 
(v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-60 %, 0.1% FA (v/v) 
acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
To expand the scope of the reaction for water soluble aldehydes  at physiological conditions, SASP 
reactions of peptide PAF 1a and PMB 3b was also investigated with water-soluble aldehydes such 
as 2-pyridinecarboxyaldehyde (2PCA) 2b and 3-hydroxy-pyridinecarbaldehyde (HPCA) 2d under 
physiological conditions. The results showed moderate conversion to Petasis products with both 
the aldehydes. On detailed analysis we found that this is due to the tendency of these aldehydes to 
generate an imidazolidinone product with the N-terminus as reported by Francis et al.22 To 
minimize the formation of the imidazolidinone product and to increase the yield of the Petasis 
product with aldehydes such as 2PCA 2b and HPCA 2d, we carried out optimization studies with 
HPCA 2d. The reagent ratios of aldehyde and boronic acid were varied. Peptide PAF 1a(15 mM) 
was reacted with aldehyde HPCA 2d (1.5–3 equiv., 22.6–45 mM) and PMB 3b (4–8 equiv., 60–
120 mM) in 25 mM phosphate buffer (pH 7.3) : DMSO (4 : 1) at room temperature for 4 h (Figure 
3.8 and Table 3.4). It was demonstrated that conversion to Petasis product was highest using 1.5 
equiv. of HPCA 2d and 8 equiv. of PMB 3b. We also observed the fast reaction rate under such 
conditions. The Petasis product 4c of peptide PAF 1a, 2PCA 2b and PMB 3b was then synthesized 
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on a larger scale and characterized by 2D NMR and HRMS (Spectra 3.8 – 3:14, Figure 3.9, Table 
3.5 – 3.6) 
 
Figure 3.8  Synthesis and LCMS of Petasis product using HPCA 
Aldehyde 
2d 
Boronic acid 
3b 
Imine 
intermediate 
N-terminal 
imidazolidinone 
product 
Petasis 
product 
3 equiv. 4 equiv. 14% 32% 55% 
1.5 equiv. 4 equiv. 16% 6% 77% 
1.5 equiv. 8 equiv. 13% 5% 81% 
Table 3. 4  Optimization of the reaction conditions for the Petasis product with HPCA 
Reaction conditions: 2 mg of peptide PAF 1a, aldehyde 2d (1.5-3 equiv.), PMB 3b (4-8 equiv.) in 
0.4 mL of 25 mM phosphate buffer (pH 7.3): DMSO (4:1) was stirred for 4 h at 37 °C. 
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Spectra 3. 8  1H NMR of Petasis product 4c  
 
Spectra 3. 9  13C NMR of Petasis product 4c 
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Spectra 3. 10  1H/1H COSY NMR of Petasis product 4c  
 
Spectra 3. 11  1H / 13C TOCSY NMR of Petasis product 4c 
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Spectra 3. 12  1H / 13C HSQC NMR of Petasis product 4c 
 
Spectra 3. 13  1H / 13C HMBC NMR of Petasis product 4c 
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Spectra 3. 14  1H / 1H ROESY NMR of Petasis product 4c 
 
Figure 3.9  Structure of Petasis product from reaction of FAP-NH2 + 4-methoxyphenylboronic acid 
+ picolinaldehyde (PCA) 
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13H NMR data for 4c 
Atom 
No. 
Chemical Shiftb 
(ppm) 
Multiplicityc Coupling Constant 
(Hz) 
Integration 
1’ 7.09 s N/A 1 
1’’ 7.51 s N/A 1 
4 3.09 d 8.8 1 
5’ 1.66-1.70 m N/A 1 
5’’ 2.01 m N/A 1 
6’ 1.61 m N/A 1 
6’’ 1.67-1.73 m N/A 1 
7’ 2.36 m N/A 1 
7’’ 2.92 m N/A 1 
9 1.14 d 6.8 3 
10 4.02 m N/A 1 
12 8.19-8.21 m N/A 1 
14 4.52 br s N/A 1 
16 8.13-8.18 m N/A 1 
18, 22 7.28-7.30 m N/A 2 
19, 21 7.26-7.28 m N/A 2 
20 7.19-7.23 m N/A 1 
24’ 2.82 dd 13.6, 9.8 1 
24’’ 3.03 dd 13.6, 4.2 1 
25 6.91-6.93 m N/A 1 
26 6.96 m N/A 1 
27 8.17-8.20 m N/A 1 
30 7.29-7.31 m N/A 1 
31 4.75 s N/A 1 
33, 37 6.84-6.88 m N/A 2 
34, 36 7.42 d 8.1 2 
39 3.71 s N/A 3 
a:  Recorded at 600 MHz in DMSO-d6 on a Bruker AVANCE III HD spectrometer 
b:  Chemical shifts referenced to TMS at 0.00 ppm 
c:  s=singlet, d=doublet, dd=doublet of doublets, br=broad, m=multiplet 
Table 3. 5  1H NMR data for 4c Chemical Shift referenced to TMS. FAP-NH2 + 4-
methoxyphenylboronic acid + picolinaldehyde (PCA) 
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13C NMR data for 4c 
Atom 
No. 
Chemical 
Shiftb 
(ppm) 
2 173.0 
4 64.2 
5 30.3 
6 23.9 
7 53.4 
9 19.3 
10 47.1 
11 171.8 
14 54.1 
15 172.8 
18, 22 129.2 
19, 21 128.0 
20 126.2 
23 138.0 
24 37.4 
25 135.8 
26 122.0 
27 148.2 
29 161.6 
30 122.6 
31 74.7 
32 158.3 
33, 37 113.7 
34, 36 128.9 
35 133.7 
39 54.9 
a:  Recorded at 151 MHz in DMSO-d6 on a Bruker AVANCE III HD spectrometer 
b:  Chemical shifts referenced to DMSO-d6 at 39.45 ppm 
Table 3. 6  13C NMR data for 4c Chemical Shift referenced to TMS. FAP-NH2 + 4-
methoxyphenylboronic acid + picolinaldehyde (PCA). 
Next, a water-soluble analogue of SAL was synthesized by combining 4-formyl-3-
hydroxybenzoicacid with propargylamine (Scheme 3.2). The resulting SAL analogue 2aʹ is highly 
soluble in water. We investigated the selectivity of aldehydes such as water-soluble SAL analogue 
2aʹ, 2PCA 2b and HPCA 2d by carrying out reactions with various N-terminal tripeptides XAF 
(where, X =Glu, Thr, Ala, Gly, Phe, Tyr, Leu, Met, Pro and Gln) and PMB 3b under optimized 
conditions. The peptides XAF 1 (12–17 mM) were reacted with aldehydes 2aʹ, 2b or 2d (1.5 equiv., 
18–25.5 mM) and PMB 3b (8 equiv., 96–136 mM) in 25mMphosphate buffer (pH 7.3) : DMSO (4 
: 1) for 4 h at 37°C. The reactions were quenched by dilution with cold water and by freezing at -
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80 °C followed by lyophilization. With aldehydes 2b and 2d, the proline terminal peptide reached 
the highest levels of conversion; although, modifications of other N-terminal peptides were also 
observed under the reaction conditions (Figure. 3.10). Despite efforts to optimize conditions for all 
N-termini for 2PCA and HPCA mediated Petasis reaction, proline still stood out as the most 
reactive species. As observed earlier with SAL 2a, the Petasis reaction with water-soluble SAL 
analogue 2aʹ was also highly chemoselective for N-terminal proline. The formation of the Petasis 
product with peptides XAF containing primary amino acids at the N-terminus was not detected 
with water-soluble SAL analogue 2a' (Figure. 3.10 , Figure A33 and Figure A34). 
 
Figure 3.10  Structure Peptide modification with Petasis reaction. Peptides with sequence XAF, 
where X represents a variable amino acid were screened for Petasis reaction with PMB 3b and a 
variety of aldehydes 2b, 2d and water-soluble SAL analogue 2aʹ. % conversion to Petasis products 
were determined by LC/MS. Reaction conditions: XAF (12–17 mM), RCHO 2 (1.5 equiv. 18–25.5 
mM), PMB 3b (8 equiv. 96–136 mM) in 25 mM buffer (pH 7.3) : DMSO (4 : 1) and 37°C. The 
samples were incubated for 4 h. Figure adopted with permission from: Sim, Y. E.; Nwajiobi, O.; 
Mahesh, S.; Cohen, R. D.; Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61. 
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3.4.4 Stability studies of the SASP product. 
Given the different reactivity of aldehydes with proline, we verified the stability of the product to 
a variety of conditions. The purified Petasis product 4b obtained from peptide PAF 1a, SAL 2a and 
PMB 3b was exposed to acidic and basic pH (pH 3.5– 10.5) at room temperature. The peptides 
were analyzed after regular intervals by LC-MS. Over the course of 24 h, the majority of the Petasis 
product 4b was stable at a pH range of 6.5 to 9.5; whereas at low pH 3.5 to 5.5, half of the Petasis 
product 4b was hydrolyzed to the starting peptide PAF 1a, as analyzed by LC-MS (Figure. 3.11). 
We hypothesized that Petasis product 4b becomes protonated under acidic conditions leading to 
the hydrolysis of Petasis product by nucleophilic attack from the neighboring ortho-hydroxyl group 
to a newly generated chiral center of the Petasis product 4b. Notably, pH had a huge effect on the 
degree of decomposition. Through substrate variation, it is likely that products of increased stability 
can be obtained for applications. To validate the process of hydrolysis, we analyzed the stability of 
Petasis product 4c obtained from the reaction of peptide PAF 1a with 2-PCA 2b (with no ortho-
hydroxyl group) and PMB 3b using LC-MS (Figure. 3.12). No degradation of the Petasis product 
4c was observed under any of tested conditions demonstrating the hydrolytic stability of the 
product. The ability of the linkage to withstand these conditions makes this method applicable for 
the development of new materials for different biological applications. 
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Figure 3.11  Stability studies of Petasis product 4b under different pH conditions. Reaction 
conditions: Petasis product 4b (1 μM) in 25 mM phosphate buffer at different pH ranging from 3.5 
to 10.5 at room temperature. The reactions were monitored by injecting the sample in HPLC/MS 
after regular intervals of time 1h, 12h and 24h. 50% hydrolysis was observed at very low pH (3.5 
to 5.5) probably due to the protonation of the proline at low pH.  
 
Figure 3.12  Stability studies of Petasis product 4c under different pH conditions.                   
Reaction conditions: Petasis product 4c (1 uM) in 25 mM phosphate buffer at different pH ranging 
from 3.5 to 10.5 at room temperature. The reaction was monitored by injecting the sample in 
HPLC/MS after regular intervals of time 1 h, 12 h and 24 h. No degradation of Petasis product 4c 
was observed even up to 24 h in different pH conditions. 
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3.4.5 Effects of pH on the rate of the SASP reaction 
The rate of the SASP reaction at different pH conditions ranging from 5.5 to 9.5 was explored on 
the model peptide PAF 1a with SAL 2a and PMB 3b. Although the rate is quite high at neutral pH 
7.3 with 62% conversion to the Petasis product 4b in 15 min, the highest conversion (80% within 
15 min) was observed at pH 9.5 (Figure. 3.13). However, considering the biocompatibility of our 
method, physiological pH is the ideal condition for promoting this reaction with peptides and 
proteins.  
 
Figure 3.13  Effect of pH on the rate of the SASP reaction. 
 Reaction conditions: PAF 1a (2 mg, 12 mM), SAL 2a (18 mM) and PMB 3b (96 mM) in 0.5 mL 
of 25 mM phosphate buffer : DMSO (4 : 1) in different pH conditions ranging from 5.5 to 9.5 and 
at room temperature. % Conversion to the Petasis product 4b was determined by injecting the 
sample in HPLC after regular intervals of time and analysis by MS. 
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Next, we explored the reactivity of primary amines at lower pH, as it could be possible to protonate 
them and therefore add boronic acids. We screened N-terminal primary tripeptides XAF with SAL 
2a/2PCA 2b and PMB 3b at pH 5.5. The results showed that SAL 2a is highly selective for N-
terminal proline even at low pH 5.5. The results with 2PCA 2b showed high reactivity with N-
terminal primary amines at low pH 5.5 as compared to physiological pH 7.3 (Figure. 3.14). It could 
be because imines generated by primary amines can protonate faster at lower pH, and therefore are 
more reactive towards boronic acids.  
  
Figure 3.14  Effect of pH on the Petasis reaction with N-terminal primary peptides. Reaction 
conditions: XAF 1a (2 mg, 12 mM), X = A, E, G, M and T, SAL 2a/2PCA 2b (18 mM) and PMB 
3b (96 mM) in 0.5 mL of 25 mM phosphate buffer (pH 5.5) : DMSO (4 : 1) at room temperature. 
% Conversion to the Petasis products were determined by injecting the sample in HPLC after 
regular intervals of time and analysis by MS. 
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3.4.6 Stereoselective nature of SASP bioconjugation 
Another unique feature of the SASP reaction is its ability to generate a new chiral center at the site 
of conjugation with high stereoselectivity. This reaction could be of a great benefit in the 
derivatization of peptides and proteins involved in drug discovery since it has been reported that 
regioselectivity and stereoselectivity are crucial for assuming the active binding conformation.30 
The analysis of the SASP product 4b showed the formation of a newly generated chiral center with 
high stereoselectivity (de >99%) and with the absolute configuration of (R) as determined by 
analysis of dipolar couplings obtained from ROESY NMR spectroscopy and by comparing the 
observed proton and carbon chemical shifts versus those calculated from density functional theory 
(Figure. 3.15a and Figure. 3.16). In addition, the DP4+ method,32 which applies a Bayesian 
statistical treatment to the NMR data, predicted the R-configuration to be the correct stereoisomer 
with greater than 99% probability. The high stereoselectivity of the SASP bioconjugation was most 
likely directed by the chirality of N-terminal proline and by the boron which guides the nucleophilic 
attack of a phenylcarbanion on the iminium ion intermediate from the Re face since attack from the 
Si face is hindered, instead of the electronic effects of other substituents33,34 (Figure. 3.15b).  
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Figure 3.15  Chemo- and stereo-selective SASP bioconjugation under physiological conditions. 
(a) NMR ROEs of Petasis product 4b are consistent with R configuration from molecular 
mechanics Monte Carlo. (b) Plausible pathway for high stereoselectivity. Figure adopted with 
permission from: Sim, Y. E.; Nwajiobi, O.; Mahesh, S.; Cohen, R. D.; Reibarkh, M. Y.; Raj, M. 
Chem. Sci. 2020, 11, 53–61. 
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Figure 3.16  Determination of the absolute configuration of the product 4b and stereoselective 
nature of SASP reaction. Comparison of ROEs from ROESY spectrum with conformers from a 
MMFF94s molecular mechanics Monte Carlo search in Spartan ’14 are consistent with the R stereo 
configuration. Key ROEs . DP4+ calculations based on experimental 13C and 1H NMR chemical 
shifts are consistent with the formation of only one diastereoisomer (de >99%). 
To further validate the role of proline for obtaining high stereoselectivity with R absolute 
configuration, the SASP reaction was performed with peptide pAF containing D-proline under the 
optimized conditions. The Petasis product 4B was obtained from the reaction of peptide pAF with 
SAL 2a and PMB 3b and characterized by 2D NMR (Spectra. 3.15 – 3.21). The analysis of the 
Petasis product 4B showed formation of a newly generated chiral center with (S) absolute 
configuration (de > 99%) which is opposite from the product obtained from peptide PAF with L-
proline (Spectra 3.15 – 3.21). This result showed that proline not only functions as a site of 
conjugation in the SASP reaction but also acts as a chiral asymmetric catalyst responsible for 
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asymmetric induction in the Petasis product 4b, 4B and 4c (Figure 3.15b, Figure 3.16, Figure. 3.17 
Figure 3.18 and Spectra. 3.15 – 3.21). 
 
Figure 3.17  Analysis of Observed ROEs Based on Spartan ’14 Modeling of the SASP product 4c. 
Comparison of ROEs from ROESY spectrum with conformers from a MMFF94s molecular 
mechanics Monte Carlo search in Spartan ’14 are consistent with the R stereoconfiguration. Key 
ROEs are shown in figure. 
 
Spectra 3. 15  1HNMR of Petasis product 4B 
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Spectra 3. 16  13CNMR of Petasis product 4B 
 
Spectra 3. 17  1H/1H COSY NMR of Petasis product 4B 
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Spectra 3. 18  1H / 13C HSQC NMR of Petasis product 4B 
 
Spectra 3. 19  1H / 13C HMBC NMR of Petasis product 4B 
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Spectra 3. 20  1H / 13C TOCSY NMR of Petasis product 4B 
 
Spectra 3. 21  1H / 1H ROESY NMR of Petasis product 4B 
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Figure 3.18  Comparison of ROEs from ROESY spectrum of SASP product 4B. 
Conformers from a MMFF94s molecular mechanics Monte Carlo search in Spartan ’14 are 
consistent with the S stereo configuration. The reaction afforded a single diastereoisomer with (de 
> 99%). D-Pro gives opposite diastereoisomer as compared to L-proline. Key ROEs are shown in 
figure above. DP4+ calculations based on experimental 13C and 1H NMR chemical shifts are 
consistent with the formation of only one diastereoisomer (de >99%). 
3.4.7 Mechanistic studies of SASP reaction: role of aldehydes. 
Aldehydes, such as salicylaldehyde SAL 2a, 2PCA 2b and HPCA 2d, were used in the initial 
studies with the view that the hydroxyl and pyridine groups at the ortho position relative to the 
aldehyde coordinates with PMB 3b by a Lewis acid–base mechanism (by dative bond), which 
brings the organoboronic acid in close proximity to the reaction center (Figure. 3.18a). Also, this 
dative bond with organoboronic acid facilitates the release of a carbanion to react with an 
electrophilic iminium ion through a favorable five-membered cyclic transition state, thereby 
generating a stable C–C bond at the site of conjugation (Figure. 3.18a). To test this proposal, a set 
of other aldehydes such as glyoxylic acid 2c, 4-hydroxy benzaldehyde 2e and 2-nitro benzaldehyde 
2f were investigated for their potential to modify the N-terminus of a model peptide PAF 1a using 
PMB 3b under optimized conditions (Figure. 3.18b, and Figure A53 – A48). Glyoxylic acid 2c 
showed progressively greater reactivity for the SASP reaction since it exhibits Lewis basic groups 
proximal to the reactive carbonyl carbon (Figure. 3.18b). Notably, Petasis products were not 
observed with 4-hydroxy benzaldehyde 2e, which contains a distal Lewis basic group, or from 2-
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nitro benzaldehyde 2f, which lacks Lewis basic group (Figure. 3.18b). The results showed that the 
presence of a Lewis base directly adjacent to the aldehyde was crucial for this reaction. Ultimately, 
SAL 2a, water-soluble SAL analogue 2aʹ, 2PCA 2b, glyoxylic acid 2c and HPCA 2d reagents 
emerged as the most effective and synthetically tractable aldehydes for further studies and 
modifications. 
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Figure 3.19  Selective dual labeling with diverse functional groups. (a) Significance of Lewis-base 
near to the aldehyde. (b) Aldehyde substrate scope and boronic acid scope with peptide PAF 1a. 
Reaction conditions. To a peptide PAF 1a (2 mg, 12 mM), in 0.5 mL solution of 25 mM phosphate 
buffer (pH 7.3) : DMSO (4 : 1) was added SAL 2a or 2PCA 2b (1.5 equiv., 18 mM) and a variety 
of boronic acids 3 (8 equiv., 96 mM). The reactions were stirred at room temperature for 2–24 h. 
Figure adopted with permission from: Sim, Y. E.; Nwajiobi, O.; Mahesh, S.; Cohen, R. D.; 
Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61. 
a 
b 
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3.4.8 Mechanistic studies of SASP reaction: Role of boronic acids in SASP reaction 
The third reagent involved in the multi-component SASP reaction is organoboronic acid. Based on 
the initial SASP reaction and the proposed mechanism, organoboronic acid acts as a nucleophile. 
The high nucleophilicity of the organoboronic acid significantly accelerates the rate of the SASP 
reaction. With this reactivity behavior in mind, various aryl- and alkenylboronic acids (3a–i) were 
screened for their potential to modify a model peptide PAF 1a with SAL 2a or 2PCA 2b under 
physiological conditions (Figure. 3.18b and Figure A35 – A48). The results showed that 
arylboronic acid with electron donating group EDGs such as para-methoxyboronic acid (PMB) 3b 
exhibited progressively greater reactivity (90% conversion in 2 h) as compared to arylboronic acid 
containing electron withdrawing groups (EWGs) such as 4-trifluoromethylphenylboronic acid 3c 
(0% conversion in 24 h) (Figure. 3.39b). Interestingly, we observed the formation of a Petasis 
product with straight chain octenylboronic acids under the reaction conditions. To confirm the 
structure of the Petasis product with octenylboronic acid, we carried out NMR on the isolated 
product obtained from the reaction of morpholine with octylenylboronic acid and SAL 2a/2PCA 
2b (Figure. A49 – A52). The substrate scope was further explored with boronic acid derivatives 
containing an alkyne group 3j and a dye, dansyl methylphenylboronic acid, 3k which can then be 
utilized for click bioconjugation and cell imaging studies, respectively. These derivatives of 
boronic acids (3j and 3k) were synthesized from commercially available 4-(2-carboxyethyl) 
benzeneboronic acid 3e and 4-(aminomethyl)phenylboronic acid (Scheme 3.3 and Scheme 3.4). 
3.4.9 SASP reaction on biologically active peptides 
The broad substrate scope of the SASP bioconjugation was determined by carrying out reactions 
with bioactive peptides with varying amino acid composition such as angiotensin I 
(PDRVYIHPFHL), a peptide hormone that causes vasoconstriction and a subsequent increase in 
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blood pressure, bradykinin (PPGFSPFR), an inflammatory mediator, and hypertrehalosemic 
neuropeptide (PVNFSPGWGT)30 by using SAL 2a and PMB 3b under optimized conditions. The 
amino acid composition of the peptide exhibited minimal impact on the degree or selectivity of the 
modification, as observed by good to excellent yields for singly modified peptides at N-terminal 
proline in all cases (Figure. 3.20 and Figure A53).  
The SASP reaction was carried out on a peptide PICSLYQLENYCN derived from chain A of 
insulin with water-soluble SAL derivatives (Figure. 3.20). The results showed single modification 
to Petasis conjugate at N-terminal proline with >80% conversion. The reaction with a 
corresponding peptide ICSLYQLENYCN containing primary amino acid at the N-terminus did not 
lead to the formation of any Petasis product. (performed at Auburn University) 
 
Figure 3.20  Secondary amine selective Petasis reaction of bioactive peptides as analyzed by ESI-
MS for angiotensin I, bradykinin, and hypertrehalosemic neuropeptide reactions with SAL 2a and 
PMB 3b. ESI-MS for insulin chain A derived peptides with water soluble SAL derivatives. 
Reaction conditions. 2 mM solution of the bioactive peptide was reacted with SAL 2a (1.5 equiv., 
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3 mM) and PMB 3b (8 equiv., 16 mM) in 0.5 mL 25 mM phosphate buffer pH 7.3 : DMSO (4 : 1) 
and reactions were stirred at room temperature for 15 h. Figure adopted with permission from: Sim, 
Y. E.; Nwajiobi, O.; Mahesh, S.; Cohen, R. D.; Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–
61. 
3.4.10 Protein scope for SASP reaction 
The SASP reaction with N-terminal amino group was first tested on native proteins such as 
myoglobin and α-lactalbumin, which contain several lysine residues (pKa = 10.6) and lack proline 
at their respective N-termini. The native proteins were reacted with water-soluble 2PCA 2b and 
reactive PMB 3b under optimized reaction conditions. We do not see any modification on these 
proteins as analyzed by MS and gels (Figure. 3.21). The protein reactions were explored with higher 
amount of 2PCA 2b (5 equiv.) and PMB 3b (50 equiv.) but any modification on these proteins were 
not observed. This could be because they have less reactive primary amino acids at the N-terminus. 
Analysis by MS demonstrated that myoglobin [m = 16950 ] and α-lactalbumin [m = 41478] did not 
show a mass increase of +197 Da. after modification. 
 
Figure 3.21 SASP reaction of Myoglobin and α-lactalbumin with 2-PCA 2b and PMB 3b.   
(a) Myoglobin and α-lactalbumin lacking N-terminal proline. No SASP product, as characterized 
by ESI-MS. (b) SDS PAGE images of proteins before and after SASP reaction. Reaction 
conditions: A protein (100 mM) was dissolved in 400 mL of 25 mM phosphate buffer pH 7.3. 
2PCA (0.5 mM) and PMB (5 mM) was added in the solution. The reaction was agitated at room 
temperature for 16 h.  
Next, N-terminal proline containing native proteins such as aldolase and creatine kinase were 
evaluated for the reaction with 2PCA 2b and PMB 3b. The protein reactions were carried out with 
116 
 
a slight excess of 2-PCA 2b (5 equiv.) and PMB 3b (50 equiv.) in 25 mM phosphate buffer (pH 
7.3) at room temperature for 16 h (Figure. 3.22 and Figure 3.24).  
Analysis by MS demonstrated that creatine kinase [m = 43 178 (+197 Da)] and aldolase [m = 39 
409 (+197 Da)] were modified by the formation of the Petasis product. We did not observe any 
second modification indicating that reaction is highly selective for N-terminal proline. 
Interestingly, the Petasis reaction with 2PCA 2b worked with a primary amino acid at the N-
terminus of peptides, but in proteins, the Petasis product was observed with more reactive N-
terminal proline containing proteins. Peptide screening in Figure. 3.10 showed that N-terminal 
amino acids can undergo Petasis reaction with 2PCA 2b, but the proline terminal peptide has 
highest conversion. Despite efforts to optimize conditions for all N-termini, proline still stood out 
as the most reactive species. When applied to protein substrates, the reaction showed a stronger 
requirement for the N-terminal proline therefore we did not observe modification of myoglobin and 
α-lactalbumin. After purification, incubation of N-terminally modified creatine kinase from a pH 
range of 3.5 to 9.5 showed full product stability over a 24 h period as detected by MS (Figure. 
3.23). 
 
Figure 3.22 SASP reaction of creatine kinase with 2-PCA 2b and PMB 3b. (a) Creatine kinase with 
N-terminal proline underwent modification to SASP product, as characterized by ESI-MS. (b) ESI-
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MS before and after SASP reaction. Reaction conditions: A protein (100 mM) was dissolved in 400 
mL of 25 mM phosphate buffer pH 7.3. 2PCA (0.5 mM) and PMB (5 mM) was added in the 
solution. The reaction was agitated at room temperature for 16 h. 
 
 
Figure 3.23  Stability studies of SASP product of protein creatine kinase (ck). The modified ck 
obtained from SASP reaction with 2-PCA 2a and PMB 3b was incubated under different pH 
conditions ranging from 3.5-9.5. Reaction conditions: ck-modified product (1 μM) was incubated 
in 25 mM phosphate buffer at different pH ranging from 3.5 to 9.5 at room temperature. The 
reaction was monitored by injecting the sample in ESI-MS after 12 h and 24 h. No degradation of 
the ck-modified Petasis product was observed after 24 h at different pH condition  
 
3.4.11 Study of protein structure and function after the modification 
To evaluate the effect of the N-terminal modification on the secondary and tertiary structure of 
aldolase, we compared the circular dichroism (CD) of the native and the SASP modified aldolase. 
The result showed no change in the secondary structure of the modified aldolase (Fig.3.24b). This 
result demonstrates that modification of the N-terminal proline on aldolase did not introduced any 
significant changes in the protein structure. Maintaining the protein secondary and tertiary structure 
after chemical modification is important to preserve the protein biological activity. 
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Figure 3.24  SASP reaction of aldolase with 2-PCA 2b and PMB 3b. (a) Aldolase with N-terminal 
proline underwent modification to SASP product, as characterized by ESI-MS. (b) CD spectra of 
aldolase before and after SASP reaction showed no change in the secondary structure of a protein. 
Reaction conditions: A protein (100 mM) was dissolved in 400 mL of 25 mM phosphate buffer pH 
7.3. 2PCA (0.5 mM) and PMB (5 mM) was added in the solution. The reaction was agitated at 
room temperature for 16 h. 
3.5 Conclusion 
In this study, we present SASP reactions for selective modification of N-terminal proline containing 
peptides and native proteins. Proline can be introduced readily in N-terminal positions using site-
directed mutagenesis.28 The SASP method reported here offer two distinct advantages over other 
N-terminal labeling methods. First, it is highly selective for N-terminal proline and does not lead 
to modification of any other amino acids. Second, it is a multicomponent reaction and dually labels 
peptides and proteins in a single step in one pot under physiological conditions, without the use of 
any catalysts. This reaction features excellent site specificity and promising scale-up potential.  
Moreover, the SASP reaction leads to the generation of a new chiral center at the site of conjugation 
with high stereoselectivity (de >99%). This is due to the ability of proline to carry out asymmetric 
synthesis. The results on a wide variety of peptides and proteins strongly indicate that the SASP 
modifies N-terminal proline residues (pKa = 10.5) even in the presence of free cysteine and lysine 
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residues which is particularly challenging due to the strong nucleophilicity of the thiol group and 
equivalent basicity of the γ – chain of lysine (pKa = 10.6) at relevant pH values. The highly selective 
nature of this reaction for N-terminal proline provide a useful bioconjugation tool that can be used 
in many bioconjugation applications such as generation of Antibody Drug Conjugates (ADC) 
where residue specific bioconjugation is critical.  Furthermore, the secondary amine selective 
nature of this reaction suggests that it could be very useful for selective tagging/enriching proteins 
with monomethyl lysine posttranslational modifications PTMs for determining their role in 
regulating various cellular signaling processes.35  
3.6 Materials and Methods 
General methods. Unless otherwise noted, the chemicals and solvents used were of analytical 
grade and were used as received from commercial sources. All commercial materials (Aldrich, 
Fluka, Nova) were used without further purification. All solvents were reagent grade or HPLC 
grade (Fisher). Aldolase from rabbit muscle, creatine phosphokinase from rabbit muscle (Type I, 
salt-free, lyophilized powder), cytochrome c from equine heart, myoglobin from equine heart 
(lyophilized powder), were purchased from Sigma Aldrich. All reactions were performed under air 
in round bottom flask. Yields refer to chromatographically pure compounds; % yield were obtained 
by comparison of HPLC peak areas of products and starting material. HPLC and MS were used to 
monitor the reaction progress. Analytical TLC was performed on EM Reagent 0.25-mm silica gel 
plates with visualization by UV irradiation at 254 nm. Purifications by column chromatography 
were performed using EM silica gel 60 (230–400 mesh). The eluting system for each purification 
was determined by TLC analysis. Chromatography solvents were used without distillation. All 
organic solvents were removed under reduced pressure using a rotary evaporator. Water (double 
distilled H2O), was purified using a Millipore Milli-Q water purification system. Centrifugations 
were performed with an Eppendorf Mini Spin Plus (Eppendorf, Hauppauge, NY). 
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Instrumentation and sample analysis.  
NMR: (NMR analysis done by Ryan Cohen at Merck, Rahway NJ) 
 1H and 13C spectra were acquired at 25 °C in DMSO-d6 using an Agilent DD2 (600 MHz) 
spectrometer with a 3-mm He triple resonance (HCN) cryoprobe. All 1H NMR chemical shifts (δ) 
were referenced relative to the residual DMSO-d5 peak at 2.50 ppm or internal tetramethylsilane 
(TMS) at 0.00 ppm. 13C NMR chemical shifts were referenced to DMSO-d6 at 39.52 ppm. 13C NMR 
spectra were proton decoupled. NMR spectral data are reported as chemical shift (multiplicity, 
coupling constants (J), integration). Multiplicity is reported as follows: singlet (s), broad singlet (br 
s), doublet (d), doublet of doublets (dd), doublet of triplets (td), triplet (t) and multiplet (m). 
Coupling constant (J) in hertz (Hz). 
LC-MS: Mass spectrometry was performed using an Agilent 1100 high performance liquid 
chromatograph coupled to an Agilent MSD VL mass spectrometer. 
HRMS and MS/MS: High resolution MS data were acquired on a Q-ToF mass spectrometer using 
positive polarity electrospray ionization (+ESI). Tandem MS experiments were performed using 
collision induced dissociation (CID) with N2 as the collision gas. 
Semi-preparative HPLC: chromatography was performed on Beckman Coulter equipped with 
System Gold 168 detector and 125P solvent module HPLC with a 10 mm C-18 reversed-phase 
column. All separations involved a mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1% 
FA (v/v) in acetonitrile (solvent B). The semi-preparative HPLC method use a linear gradient of 
0–80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate of 3.0 
mL min-1. The eluent was monitored by absorbance at 220 nm and 254 nm unless otherwise noted. 
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Analytical HPLC: Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100 
series HPLC equipped with a 4.6 mm C-18 reversed-phase column. All separations involved mobile 
phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide 
compositions were evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in 
acetonitrile versus 0.1% FA in water. Analytical HPLC method use a linear gradient of 0-60% or 
0-80% 0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a 
flow rate of 1.0 mL min-1. The eluent was monitored by absorbance at 220 nm unless otherwise 
noted. 
Gel analysis: For protein analysis, sodium dodecyl sulfate-PAGE (SDS-PAGE) was carried out on 
a Mini-Protean apparatus (Bio-Rad, Hercules, CA), using a 10-20% precast linear gradient 
polyacrylamide gel (Bio-Rad). Gels were run for 80 min at 120 V to separate the bands. 
Commercially available markers (Bio-Rad) were applied to at least one lane of each gel for 
assignment of apparent molecular masses. Visualization of protein bands was accomplished by 
staining with Coomassie Brilliant Blue R-250 (Bio-Rad). 
Peptide library synthesis. General procedure for solid-phase peptide synthesis:42 Peptides 
were synthesized manually on a 0.25 mm scale using Rink amide resins. Fmoc–group was 
deprotected using 20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. The side 
chain protecting groups used were: Asn(Trt), Cys(Trt), Asp(tBu), Glu(tBu), His(Trt), Lys(Boc), 
Gln(Trt), Arg(Pbf), Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu). Fmoc-protected amino acids (1.25 
mm) were sequentially coupled on the resin using HBTU (1.25 mm) and DIEA (1.25 mm) for 2 h 
at room temperature. Peptides were synthesized using standard protocols. Side chain deprotection 
and the peptide was cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic 
acid:triisopropylsilane:water for 2 h. The resin was removed by filtration and the resulting solution 
was concentrated. The oily residue was triturated with diethyl ether to obtain a white suspension. 
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The resulting solid was purified by reverse-phase HPLC with a gradient of H2O/CH3CN with 0.1% 
FA. The organic solvent was removed on a vacuum centrifuge, and the remaining water was 
removed by lyophilization.  
Peptide modification. General method for the modification of peptides with SASP reaction 
using aldehydes and boronic acid in one pot.  
All aldehydes and boronic acids were purchased from Sigma Aldrich. To a 2 mg peptide XAF 1 
(12-17 mM) in 0.4 mL of 25 mM phosphate buffer (pH 7.3) : DMF (4:1) was added SAL 2a (3 
equiv., 36 mM-51 mM) and PBA 3a (4 equiv., 48 mM-68 mM). The reaction was stirred at room 
temperature for 4-24 h. The reaction was analyzed by MS and purified by HPLC to obtain white 
solid. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 
0-60 % or 0-80 %, depending on nature of peptides, 0.1% FA (v/v) acetonitrile in 25 min, flow rate 
= 1.0 mL/min, detection wavelength 220 nm. 
General method for the verification of the chemoselective nature of SASP reaction: To mixture 
of peptides PAF 1a (2 mg, 15 mM) and XAF 1 (2 mg, 12-17 mM) in 0.4 mL of 25 mM phosphate 
buffer (pH 7.3) : DMF (4:1) was added SAL 2a (3 equiv., 36 mM-51 mM) and PBA 3a (4 equiv., 
48 mM-68 mM). The solution was stirred at room temperature for 24 h. The reaction was analyzed 
by LC/MS. LC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 
0-60 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 
nm. 
Synthesis of small molecules. L-Pro-L-Ala-L-Phe SASP product 4b with SAL and PMB: To 
a solution of L-Pro-L-Ala-L-Phe PAF 1a (8 mg, 0.024 mmol) in 25 mM phosphate buffer (pH 7.3) 
: DMSO (4:1) (1 mL) was added SAL 2a (8.72 mg, 0.072 mmol) and PMB 3b (14.5 mg, 0.096 
mmol). The resulting solution was stirred at room temperature. After 16 h, the reaction was 
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concentrated by lyophilization. The resulting material was purified by HPLC to afford the product 
4b as a single diastereomer. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile 
(solvent B); gradient 0-60 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, 
detection wavelength 220 nm. 
Single diastereomer: 1H NMR (600 MHz, DMSO-d6): δ 9.98 (s,1H), 8.15 (d, J = 7.7 Hz, 1H), 8.06 
(d, J = 8.2 Hz, 1H), 7.48 (s, 1H), 7.35 (d, J = 8.2 Hz, 2H), 7.28 (m, 2H), 7.26 (m, 2H), 7.19 (t, J = 
6.9 Hz, 1H), 7.08 (s, 1H), 7.02 (d, J = 7.4 Hz,1H), 6.87 (d, J = 8.2 Hz, 2H), 6.79 (d, J = 7.7 Hz,1H), 
6.66 (t, J = 7.7 Hz,1H), 6.03 (brs,1H), 5.10 (s,1H), 4.52 (m,1H), 4.05 (p, J = 7.0 Hz,1H), 3.71 (s, 
3H), 3.14 (m,1H), 3.02 (dd, J = 13.8, 4.8 Hz,1H), 2.91 (m,1H), 2.82 (dd, J = 13.8, 9.6 Hz,1H), 2.44 
(m,1H), 1.98 (m,1H),1.69 (m,1H), 1.67 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H); 13C NMR (151 MHz, 
DMSO-d6): 173.1, 172.8, 171.8,157.9, 154.5, 137.8, 134.8, 129.1,129.0, 128.7, 128.1, 128.0, 127.2, 
126.2, 118.3, 115.1,113.6, 64.2, 63.4, 54.9, 53.9, 53.0, 47.2, 37.5, 30.2, 23.9, 19.2.  
See Spectra 3.1 – 3.7  for  1H, 13C, COSY, HSQC, HMBC, TOCSY and ROESY NMR spectra. 
 
Scheme 3.1  Synthesis of small molecules. L-Pro-L-Ala-L-Phe SASP product 4b with SAL and 
PMB. 
Synthesis of small molecules. PAF SASP product 4c with 2PCA and PMB. To a solution of 
PAF 1a (8 mg, 0.024 mmol) in 25 mM phosphate buffer pH 7.3: DMSO (4:1) (1 mL) was added 
2PCA 2b (3.85 mg, 0.036 mmol) and PMB 3b (29.0 mg, 0.192 mmol). The resulting solution was 
stirred at room temperature. After 16 h, the reaction was concentrated by lyophilization. The 
resulting material was purified by HPLC to afford the product 4c as a single diastereomer. HPLC: 
0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-60 %, 0.1% 
FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
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Single diastereomer 1H NMR (600 MHz, DMSO-d6): δ 8.20 (m, 1H), 8.18 (m, 1H), 8.16 (m, 1H), 
7.51 (s,1H), 7.42 (d, J = 8.1 Hz, 2H), 7.30 (m, 1H), 7.09 (s, 1H), 7.29 (m, 2H), 7.27 (m, 2H), 7.21 
(m, 1H), 6.96 (m, 1H), 6.92 (m, 1H), 6.86 (m, 2H), 4.75 (s, 1H), 4.52 (br s, 1H), 4.02 (m, 1H), 
3.71 (s, 3H), 3.09 (d, J = 8.8 Hz, 1H), 3.03 (dd, J = 13.6, 4.2 Hz, 1H), 2.92 (m, 1H), 2.82 (dd, J = 
13.6, 9.8 Hz, 1H), 2.36 (m, 1H), 2.01 (m, 1H), 1.70 (m, 1H), 1.68 (m, 1H), 1.61 (m, 1H), 1.14 (d, 
J = 6.8 Hz, 3H); 13C NMR (151 MHz, DMSO-d6): 173.0, 172.8, 171.8, 161.6, 158.3, 148.2, 
138.0, 135.8, 133.7, 129.2, 128.9, 128.0, 126.2, 122.6, 122.0, 113.7, 74.7, 64.2, 54.9, 54.1, 53.4, 
47.1, 37.4, 30.3, 23.9, 19.3. See spectra 3.8 – 3.14  for 1H, 13C, COSY, HSQC, HMBC, TOCSY 
and ROESY NMR spectra. 
General method for the synthesis of water-soluble analogs of SAL. To a mixture of 4-formyl-
3-hydroxybenzoic acid, DIEA, PyBOP in DMF was added propargyl amine or 1-Boc-piperazine 
dropwise over 5 mins and reaction mixture was stirred at room temperature for 16 h. Reaction 
mixture was diluted with ethyl acetate and extracted with water followed by washing of organic 
layer with brine solution thrice. Combined ethyl acetate layers were dried with sodium sulfate and 
volatiles were removed under reduced pressure. Crude reaction mixture was purified over silica 
gel using 30 % ethyl acetate and hexane as an eluent to generate pure derivatives of 4-formyl-3-
hydroxybenzoicacid. 
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Scheme 3.2  General method for the synthesis of water-soluble analogs of SAL. 
Stability of Petasis bioconjugate. Method for determining the hydrolytic stability of Petasis 
product 4b and 4c under different pH conditions: To a Petasis product 4b or 4c (1 μM), 0.5 mL 
of 25 mM phosphate buffer (pH ranging from 3.5 to 9.5) : ACN (9:1) was added and the resulting 
solution was stirred at room temperature. The stability of the products 4b and 4c were monitored 
by injecting samples in the HPLC after regular intervals 1 h, 12 h and 24 h. % Conversion to the 
degraded product was determined by calculating areas under the peak in HPLC. HPLC: 0.1% FA 
(v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-60 %, 0.1% FA (v/v) 
acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. The characterization 
of the degraded product of 4b was analyzed by MS. 
Rate of SASP reaction. Method for testing the effect of pH on the rate of the SASP reaction: 
To a solution of PAF 1a (2 mg, 12 mM) in 0.5 mL of 25 mM phosphate buffer (pH ranging from 
5.5 to 9.5): DMSO (4:1) was added SAL 2a (1.5 equiv., 18 mM) and PMB 3b (8 equiv., 96 mM). 
The resulting solution was stirred at room temperature for 2h. The reaction was quenched by 
diluting with water and by freezing at -80 °C. The samples were concentrated by lyophilization, 
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analyzed by MS and monitored by injecting reaction in HPLC after regular intervals of time 15 
min, 30 min, 1 h and 2 h. % Conversion to the Petasis product 4b was determined by calculating 
areas under the peak in HPLC. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) 
acetonitrile (solvent B); gradient 0-60 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 
mL/min, detection wavelength 220 nm. 
Method for analysis of diastereoselectivity of SASP reaction and determination of the 
absolute configuration of SASP product. Product 4b obtained by reaction of peptide PAF 
with SAL, and PMB: The relative stereochemistry of SASP product 4b was determined by 
through-space correlations (i.e., ROEs) from the ROESY spectrum and then verified by 
computational chemistry predictions of the NMR chemical shifts. DFT calculations (PCM-
mPW1PW91/6-31+G**//B3LYP/6-31G*) of 1H and 13C chemical shifts for the Petasis product 4b 
was performed. The calculated chemical shifts were Boltzmann averaged based on the conformer 
distribution. There were 13 conformers less than 5 kcal/mol in energy for the S-configuration and 
14 conformers less than 5 kcal/mol for the R-configuration. In both cases, there was a single 
dominant conformer accounting for greater than 40% of the Boltzmann population. Using the DP4+ 
method, the R-configuration was predicted to be the correct stereoisomer with >99% probability. 
See Figure 3.16 for details. 
Synthesis of small molecules. D-Pro-L-Ala-L-Phe SASP product 4B with SAL and PMB: To 
a solution of D-pro-L-Ala-L-Phe pAF 1B (8 mg, 0.024 mmol) in 25 mM phosphate buffer pH 7.3: 
DMSO (4:1) (1 mL) was added SAL 2a (4.36 mg, 0.036 mmol) and PMB 3b (29.0 mg, 0.192 
mmol). The resulting solution was stirred at room temperature. After 16 h, the reaction was 
concentrated by lyophilization. The resulting material was purified by HPLC to afford the product 
4B as a single diastereomer. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile 
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(solvent B); gradient 0-60 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, 
detection wavelength 220 nm. 
Single diastereomer: 1H NMR (600 MHz, DMSO-d6): δ 9.91 (s, 1H), 8.12 (d, J = 7.7 Hz, 1H), 
7.95 (d, J = 8.2 Hz, 1H), 7.45 (s, 1H), 7.35 (d, J = 8.2 Hz, 2H), 7.29-7.27 (m, 2H), 7.27-7.24 (m, 
2H), 7.19 (t, J = 6.9 Hz, 1H), 7.08 (s, 1H), 7.02 (d, J = 7.4 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.75 
(d, J = 7.7 Hz, 2H), 6.66 (t, J = 7.7 Hz, 1H), 6.55 (m,1H), 5.10 (s,1H), 4.55-4.49 (m,1H), 4.10 (p, 
J= 7.0 Hz,1H), 3.71 (s, 3H), 3.14 (m,1H), 3.02 (dd, J = 13.8, 4.8 Hz,1H), 2.91 (m,1H), 2.82 (dd, J 
= 13.8, 9.6 Hz,1H), 2.44 (m,1H), 1.98 (m,1H), 1.74-1.60 (m, 2H), 1.72-1.65 (m,1H), 1.13 (d, J = 
6.8 Hz, 3H); 13C NMR (151 MHz, DMSO-d6): 173.2, 172.6, 171.7, 157.9, 154.8, 137.7, 134.1, 
129.1, 129.0, 128.9, 128.3, 127.9, 127.5, 126.1, 118.5, 115.3, 113.6, 63.9, 63.6, 54.9, 53.5, 52.7, 
47.7, 37.6, 30.1, 23.9, 18.3. See Spectra 5.15 – 3.21 for 1H, 13C, COSY, HSQC, HMBC, TOCSY 
and ROESY NMR spectra. 
General method for screening of aldehydes with peptide PAF 1a: To a peptide PAF 1a (2 mg, 
12 mM) in 0.5 mL solution of 25 mM phosphate buffer (pH 7.3) : DMSO (4:1) was added a variety 
of aldehydes (1.5 equiv., 18 mM) and PBA 3a/PMB 3b (8 equiv., 96 mM). The reactions were 
stirred at room temperature for 4-24 h. The reactions were analyzed by LC/MS. LC: 0.1% FA (v/v) 
in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-60 % or 0-80 %, depending 
on nature of peptides, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection 
wavelength 220 nm. 
General method for screening of boronic acids with peptide PAF: To a peptide PAF 1a (2 mg, 
12 mM), in 0.5 mL solution of 25 mM phosphate buffer (pH 7.3) : DMSO (4:1) was added SAL 
2a or 2PCA 2b (1.5 equiv., 18 mM) and a variety of boronic acids (8 equiv., 96 mM). The reactions 
were stirred at room temperature for 2-24 h. The reactions were analyzed by LC/MS. LC: 0.1% FA 
(v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-60 % or 0-80 %, 
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depending on nature of peptides, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, 
detection wavelength 220 nm. 
 
Scheme 3.3  Synthesis of alkyneboronic acid 3j  
To a solution of 4-(2-Carboxyethyl)benzeneboronic acid (100 mg) and PyBOP (1 equiv.) in DMF, 
propargylamine (2 equiv.) was added followed by addition of DIEA (3.2 equiv.). The reaction 
mixture was stirred overnight at room temperature. The reaction was analyzed by HRMS and 
purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) 
acetonitrile (solvent B); gradient 0-80 % with flow rate = 1.0 mL/min, detection wavelength 220 
nm. 
 
Scheme 3.4  Synthesis of dansylboronic acid 3k:  
To 1.0 mL solution of dansyl chloride (1.5 equiv.), diisopropyl amine (1.5 equiv.) in DMF, 4-
(aminomethyl)phenylboronic acid (20 mg) was added. The solution was stirred at room temperature 
for 12 h. The reaction was analyzed by MS and purified by HPLC to obtain yellow solid. HPLC: 
0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 
depending on nature of peptides, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, 
detection wavelength 220 nm. 
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Chapter 4 
Contribution to Knowledge and Future Work 
4.1 Contribution to Knowledge and Future Work  
4.1.1 Serine Promoted Synthesis of Peptide Thioester-Precursor on Solid Support for 
Native Chemical  
Native Chemical Ligation is an important technique for chemical protein synthesis and site-
selective protein modification. It relies on the reaction of a peptide thioester with a N-terminal 
cysteine peptide.  Since the direct synthesis of peptide thioester by Fmoc based peptide synthesis 
is not practical because of the instability of the thioester moiety during the repeated deprotection 
steps with piperdine, thioester precursors that can efficiently converted into thioesters is highly 
desired. 
Chapter 2 of this thesis provides a protocol for solid phase synthesis of C-terminal peptide thioester 
using Fmoc based chemistry. The method independent of the type of resins, linkers and unnatural 
amino acids typically needed for the synthesis of peptide thioester using Fmoc chemistry. It utilizes 
a cyclic urethane technique (CUT) to synthesize a cyclic urethane or oxazolidinone (Oxd) moiety 
from a C-terminal native serine residue after peptide elongation. Fast and efficient nucleophilic 
displacement of this activated moiety with a thiol under mild conditions generates a peptide 
thioester. The utilization of this technique was demonstrated by the synthesis of a 29 amino acid 
long peptide derived from rabies virus glycoprotein (Rvg) using NCL. The method is a useful tool 
in chemical biology for the synthesis of unprotected peptide thioester for use in NCL. 
Future work on this project should explore the applicability of this methodology to synthesize 
difficult protein. 
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4.1.2 Secondary Amine Selective Petasis (SASP) 
Site-Selective chemical modification is important strategy for preparing well-defined 
bioconjugates for many applications in chemical biology and biotherapeutics. Traditional 
modification approach lack site selectivity since it is challenging to modify a single site in the 
presence of multiple competing targets. Although many successful methods have been developed 
for site selective modification, an efficient method to modify a single native residue at a specific 
site on the protein is elusive. 
Chapter 3 of this thesis describes a novel strategy that is highly selective for modification of 
secondary amine and N-terminal proline. The strategy is derived from the classical Petasis reaction 
which forms stable bonds at the site of conjugation between amine, aldehyde and organoboron 
reagents. The method exploited the ability for secondary amines to form highly electrophilic 
iminium ion with aldehydes, then rapidly react with nucleophilic organoboron reagents under mild 
conditions for protein modification. The reaction is highly chemoselective and stereoselective and 
affords dual labelling in one pot. It also generates a new chiral centre at the site of conjugation with 
high selectively. The utilization of this strategy was demonstrated on various peptides and protein, 
including aldose and creatine kinase.  
Future work on the project includes: 
1. To demonstrate the applicability of this methodology to tag and study proteins with 
secondary amine functionalities such as monomethylated lysine post translation 
modification PTM to determine their role in regulating various cellular signalling 
processes. 
2. To demonstrate the applicability of this methodology to modify glycoprotein such as 
antibodies by oxidizing the carbohydrate residues at vicinal diols to generate an aldehyde 
substrate for the SASP reaction. This strategy can be used to generate conjugates to study 
protein function and construct new therapeutic conjugates.  
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CHAPTER 2 SUPPLEMENTARY FIGURES 
All of the following figures have been reproduced with permission from: Elashal, H. E.; Sim, 
Y. E.; Raj, M. Chem. Sci., 2017, 8, 117–123.  
Synthesis and Characterization of cyclic urethane peptides 
 
 
Figure A.1  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Ac-GlyGly-
Oxd-Ala-Ala-Gly-NH2 (2a) 
Ac-Gly-Gly-Ser-Ala-Ala-Gly-NH2 (1a). LCMS: m/z 460.2 (calcd [M+H]+ = 460.5), m/z 482.2 
(calcd [M+Na]+ = 482.5). Purity: >95% (HPLC analysis at 220 nm). Retention time: 4.5 min. 
Ac-Gly-Gly-Oxd-Ala-Ala-Gly-NH2 (2a). LCMS: m/z 486.1 (calcd [M+H]+ = 486.4), m/z 
508.1(calcd [M+Na]+ = 508.4). Purity: >95% (HPLC analysis at 220 nm). Retention time: 4.8 min. 
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Figure A.2  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Ac-Gly-Gly-
Oxd-Ala-Ala-Gly-NH2 -2a  
Ac-Gly-Gly-Oxd-Ala-Ala-Gly-NH2 (2a). LCMS: m/z 486.1 (calcd [M+H]+ = 486.4), m/z 
508.1(calcd [M+Na]+ = 508.4). Purity: >95% (HPLC analysis at 220 nm). Retention time: 4.8 min 
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Figure A.3  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Fmoc-Ala-
Oxd-Phe-NH2 (2b).  
LCMS: m/z 571.0 (calcd [M+H]+ = 571.3). Purity: >95% (HPLC analysis at 220 nm).  
Retention time: 18.1 min  
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Figure A.4  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Ac-Ala-
Oxd-Phe-NH2 (2c).  
LCMS: m/z 391.1 (calcd [M+H]+ = 391.5). Purity: >95% (HPLC analysis at 220 nm).  
Retention time: 9.89 min 
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Figure A.5  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Ts-Ala-Oxd-
Phe-NH2 (2d). 
LCMS: m/z 503.1 (calcd [M+H]+ = 503.2). Purity: >95% (HPLC analysis at 220 nm).  
Retention time: 13.45 min 
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Figure A.6  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Ala-Oxd-
Phe-NH2 (2e). 
LCMS: m/z 349.2 (calcd [M+H]+ = 349.5). Purity: >95% (HPLC analysis at 220 nm).  
Retention time: 5.91 min 
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Figure A.7  Synthesis, LCMS and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-
Phe-Ala-Oxd-NH2 (2f). 
LCMS: m/z 628.2 (calcd [M+H]+ = 628.5). Purity: >95% (HPLC analysis at 220 nm).  
Retention time: 13.9 min 
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Figure A.8  Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-Ala-Oxd-
Phe-Ala-Gly-NH2 (2aʹ) 
LCMS: m/z 756.40 (calcd [M+H]+ = 756.10), 778.5 (calcd [M+Na]+ = 778.0). Purity: >95% (HPLC 
analysis at 254 nm).  
Retention time: 17.9 min. 
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Figure A.9  Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-Gly-Oxd-
Phe-Ala-Gly-NH2 (2bʹ). 
LCMS: m/z 742.40 (calcd [M+H]+ = 742.50), 371.9 (calcd [(M+2]2+ = 371.75). Purity: >95% 
(HPLC analysis at 254 nm).  
Retention time: 20.1min. 
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Figure A.10  Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-Met-
Oxd-Phe-Ala-Gly-NH2 (2cʹ). 
LCMS: m/z 816.0 (calcd [M+H]+ = 816.20), 408.2 (calcd (M+2)2+ = 408.8). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 21.8 min. 
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Figure A.11  Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-His-Oxd-
Phe-Ala-Gly-NH2 (2dʹ).     
LCMS: m/z 822.10 (calcd [M+H]+ = 822.60), 411.2 (calcd (M+2)2+ = 411.79). Purity: >95% (HPLC 
analysis at 254 nm).  
Retention time: 16.9 min. 
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Figure A.12  Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-Tyr-
Oxd-Phe-Ala-Gly-NH2 (2eʹ). 
LCMS: m/z 848.20 (calcd [M+H]+ = 848.62), 424.1 (calcd [(M+2)2+ = 424.81). Purity: >95% 
(HPLC analysis at 254 nm).  
Retention time: 21.1 min. 
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Figure A.13   Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-Trp-
Oxd-Phe-Ala-Gly-NH2 (2fʹ).  
LCMS: m/z 871.20 (calcd [M+H]+ = 871.6), 436.0 (calcd (M+2) = 436.33) 2+.Purity: >95% (HPLC 
analysis at 254 nm). 
Retention time: 19.8 min. 
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Figure A.14  Synthesis and HPLC trace of cyclic urethane containing peptide Fmoc-Gly-Val-
Oxd-Phe-Ala-Gly-NH2 (2gʹ). 
LCMS: m/z 784.60 (calcd [M+H]+ = 784.58), 392.5 (calcd (M+2) 2+ = 392.79). Purity: >95% (HPLC 
analysis at 254 nm). 
Retention time: 16.6 min. 
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Synthesis and Characterization of peptide thioesters 
 
 
 
 
 
Figure A.15  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Gly-Pro-Met-Leu-Ala-
COS(CH2)2OH (3g) and hydrolysis product Ac-Gly-Pro-Met-Leu-Ala-OH. 
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2OH (3g) LCMS: m/z 590.2 (calcd [M+H]+ = 590.6), m/z 
612.2 (calcd [M+ Na]+ = 612.6). Purity: >95% (HPLC analysis at 220 nm) 
 Retention time:10.28 min 
 
Ac-Gly-Pro-Met-Leu-Ala-OH. LCMS: m/z 530.2 (calcd [M+H]+ = 530.5), m/z 552.2 (calcd 
[M+Na]+ = 552.5). Purity: >95% (HPLC analysis at 220 nm). 
 Retention time: 9.36 min 
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Figure A.16  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Gly-Pro-Met-Leu-Ala-
COS(CH2)2CO2C2H5 (3G).  
LCMS: m/z 646.3 (calcd [M+H]+ = 646.7). Purity: >95% (HPLC analysis at 220 nm). Retention 
time: 13.87 min 
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Figure A.17  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Ala-Val-Gly-Pro-Pro-
Gly-Val-Ala-COS(CH2)2CO2C2H5 (3h). 
LCMS: m/z 825.3 (calcd [M+H]+ = 825.7), m/z 847.3 (calcd [M+Na]+ = 847.7). Purity: >95% 
(HPLC analysis at 220 nm).  
Retention time: 11.94 min 
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Figure A.18  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Arg-Ala-Phe-Lys-Tyr-
Gly-Leu-Glu-COS(CH2)2CO2C2H5 (3i). 
LCMS: m/z 1140.9 (calcd [M+H]+ = 1140.5), m/z 1163.9 (calcd [M+Na]+ = 1163.5). Purity: >95% 
(HPLC analysis at 220 nm).  
Retention time: 19.45 min. 
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Figure A.19  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Gly-Val-Ala-Leu-Phe-
COS(CH2)2CO2C2H5 (3j). 
LCMS: m/z 664.3 (calcd [M+H]+ = 664.6), m/z 686.3 (calcd [M+Na]+ = 686.6). Purity: >95% 
(HPLC analysis at 220 nm).  
Retention time:16.30 min. 
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Figure A.20  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Tyr(tBu)-Phe-Asp(tBu)-
Ile-Arg(Pbf)-Ala-Val-COS(CH2)2CO2C2H5 (3k). 
LCMS: m/z 1404.7 (calcd [M+H]+ = 1404.3), m/z 1426.5 (calcd [M+Na]+ = 1426.3). Purity: >95% 
(HPLC analysis at 220 nm). 
Retention time: 25.09 min 
. 
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Figure A.21  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Tyr-Phe-Asp-Ile-Arg-
Ala-Val-COS(CH2)2CO2C2H5 (3K).  
LCMS: m/z 1040.7 (calcd [M+H]+ = 1040.8), m/z 1063.6 (calcd [M+Na]+ = 1063.8). Purity: >95% 
(HPLC analysis at 220nm).  
Retention time: 14.61 min. 
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Figure A.22   Synthesis, LCMS and HPLC trace of peptide thioester Ac-Ser-Gly-Ile-Ser-Gly-
Pro-Leu-Ser-COS(CH2)2CO2C2H5 (3L). 
LCMS: m/z 875.3 (calcd[M+H] + = 875.7), m/z 897.2 (calcd [M+Na]+ = 897.7). Purity: >95% 
(HPLC analysis at 220 nm). 
Retention time: 12.0 min 
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Figure A.23  Synthesis, LCMS and HPLC trace of peptide thioester Ac-Arg-Phe-Ala-Thr-
COS(CH2)2CO2C2H5 (3M). 
LCMS: m/z 651.8 (calcd [M+H]+ = 651.5), m/z 673.8 (calcd [M+Na]+ = 673.5). Purity: >95% 
(HPLC analysis at 220 nm).  
Retention time: 11.01 min. Isolated yield = 50 % 
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Figure A.24  Synthesis, LCMS and HPLC trace of peptide thioester Fmoc-Gly-Pro-Met-Leu-
Ala-OxdMe (2n). 
LCMS: m/z 835.9 (calcd [M+H]+ = 835.7), m/z 857.8(calcd [M+Na]+ = 857.7). Purity: >95% (HPLC 
analysis at 220 nm).  
Retention time: 18.4 min. 
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Figure A.25  Synthesis, LCMS and HPLC trace of peptide thioester Fmoc-Gly-Pro-Met-Leu-
Ala-Thz (2o). 
LCMS: m/z 837.8 (calcd [M+H]+ = 837.7), m/z 859.8 (calcd [M+Na]+ = 859.7). Purity: >95% 
(HPLC analysis at 220 nm).  
Retention time: 18.39 min. 
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Figure A.26  Synthesis, LCMS and HPLC trace of peptide thioester  
Ac-RMITYGNSARKGRSNTFID-COS(CH2)2CO2C2H5 (3P). 
LCMS: m/z 1172.8 (calcd[M+2H]2+ = 1172.5), m/z 782.1 (calcd [M+3H]3+ = 782.0), m/z 586.6 
(calcd [M+4H]4+= 586.7). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 10.67 min. Isolated yield = 31% 
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Figure A.27  Synthesis, LCMS and HPLC trace of peptide thioester  
Ac-GNSARKGRSNTFID-COS(CH2)2CO2C2H5 (3Q) 
LCMS: m/z 840.4 (calcd [M+2H]2+ =840.9), m/z 560.7 (calcd [M+3H]3+ = 560.9). Purity: >95% 
(HPLC analysis at 220 nm). 
Retention time: 9.88 min. Isolated yield = 39 % 
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Native Chemical Ligation 
 
 
Figure A.28  Native Chemical Ligation reaction before quenching it with TCEP.HCl 
Ac-Gly-Pro-Met-Leu-Ala-Cys(MPAA)-Arg-Phe-Ala-Ser. LCMS: m/z 1285.5 (calcd [M+Na]+ 
= 1285.8). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 13.2 min 
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Figure A.29  Native Chemical Ligation reaction after quenching it with TCEP.HCl 
Ac-Gly-Pro-Met-Leu-Ala-Cys-Arg-Phe-Ala-Ser.  
LCMS: m/z 1093.4 (calcd [M+H]+ = 1093.3), m/z 547.2 (calcd [M+2]2+ = 547.6). Purity: >95% 
(HPLC analysis at 220 nm).  
Retention time:11.32 min. 
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Figure A.30  Native Chemical Ligation reaction after quenching it with TCEP.HCl 
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Cys-Arg-Phe-Ala-Ser. LCMS: m/z 1273.6 
(calcd [M+H]+ = 1273.4), m/z 636.9 (calcd [M+2]2+ = 637.2). Purity: >95% (HPLC 
analysis at 220 nm). 
Retention time: 10.01 min. 
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Figure A.31  Native Chemical Ligation reaction after quenching it with TCEP.HCl 
Ac-GNSARKGRSNTFIDCPTGPRPNEPMWITY-NH2.  
LCMS: m/z 3308.6 (calcd [M+H]+ = 3308.4), m/z 1654.8 (calcd [M+2]2+ = 1654.7). Purity: >95% 
(HPLC analysis at 220 nm). 
Retention time: 11.14 min 
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Figure A.32 MALDI of ligated Product 29 amino acid long peptide                                                                                  
Ac-GNSARKGRSNTFIDCPTGPRPNEPMWITY-NH2 
 
 
 
 
 
 
 
 
  
171 
 
CHAPTER 3 SUPPLEMENTARY FIGURES 
The following figures have been reproduced with permission from: Sim, Y. E.; Nwajiobi, O.; 
Mahesh, S.; Cohen, R. D.; Reibarkh, M. Y.; Raj, M. Chem. Sci. 2020, 11, 53–61 
 
Figure A.33  HRMS of reaction of peptide PAF 1a, HPCA 2d and PMB 3b.  
 
Figure A.34  HRMS of the reaction of peptide PAF 1a, water-soluble SAL analog 2aʹ and PMB 
3b. 
 
Figure A.35  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and PBA 3a. 
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Figure A.36  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and PMB 3b. 
 
Figure A.37  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
2PCA 2b and PBA 3a. 
 
Figure A.38  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
2PCA 2b and PMB 3b 
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Figure A.39  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
glyoxylic 2c and PMB 3b. 
 
Figure A.40  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with SAL 
2a and styryl boronic acid 3d. 
 
Figure A.41  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and 4-(2-carboxyethyl) benzene BA 3e. 
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Figure A.42  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and fluorene boronic acid 3f. 
 
Figure A.43  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
2PCA 2b and octenyl boronic acid 3g. 
 
 
Figure A.44  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with SAL 
2a and octenyl boronic acid 3g. 
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Figure A.45  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and vinyl boronic acid 3h. 
 
Figure A.46  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and 2,6 dimethoxy-4-methylphenyl boronic acid 3i. 
 
Figure A.47  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and alkyne boronic acid 3j. 
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Figure A.48  HRMS of SASP product obtained from Petasis reaction on peptide PAF 1a with 
SAL 2a and dansyl boronic acid 3k. 
 
Figure A.49  1H NMR of SASP product obtained by the reaction of morpholine with 
octenylboronic acid and SAL 2a 
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Figure A.50  13C NMR of SASP product obtained by the reaction of morpholine with 
octenylboronic acid and SAL 2a 
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Figure A.51  1H NMR of SASP product obtained by the reaction of morpholine with 
octenylboronic acid and 2PCA 2b 
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Figure A.52  13C NMR of SASP product obtained by the reaction of morpholine with 
octenylboronic acid and 2PCA 2b 
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Figure A.53  HRMS of bioactive peptides after modification with SAL 2a and PMB 3b. Shown 
are representative mass spectra of modified bioactive peptides after a 2 mM solution of the peptide 
was reacted with SAL 2a (1.5 equiv., 3 mM) and PMB 3b (8 equiv., 16 mM) in 0.5 mL 25 mM 
phosphate buffer pH 7.3: DMSO (4:1) and reactions were stirred at room temperature for 15 h. The 
reactions were analyzed by LC-MS 
